[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fD9_Bae2dt5XL5FkCBELTTg1TprpietBMmVEbNy9Sbl0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":82,"rows":89},"Ohio State University Comprehensive Cancer Center",[4],362,false,108,2,262244,42,236,[14,17,20,23,26,28,31,34],{"name":15,"count":16},"Breast Cancer",23,{"name":18,"count":19},"Anatomic Stage II Breast Cancer AJCC v8",16,{"name":21,"count":22},"Anatomic Stage III Breast Cancer AJCC v8",15,{"name":24,"count":25},"Malignant Solid Neoplasm",14,{"name":27,"count":25},"Tobacco-Related Carcinoma",{"name":29,"count":30},"Anatomic Stage I Breast Cancer AJCC v8",13,{"name":32,"count":33},"Breast Carcinoma",12,{"name":35,"count":36},"Cigarette Smoking-Related Carcinoma",11,[38,43,48,53,58,62,67,70,74,78],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT04780568","Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer","2026-07-31","Osimertinib",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT02940301","Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma","2026-08-15","Ibrutinib",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT03824327","Papaverine and Stereotactic Body Radiotherapy (SBRT) for Non Small Cell Lung Cancer (NSCLC) or Lung Metastases","2026-08-31","Papaverine Hydrochloride",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT05336812","Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia","2026-10-31","Acalabrutinib",{"nctId":59,"briefTitle":60,"date":56,"intervention":61},"NCT06223659","EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers","Eutectic Mixture of Local Anesthetics",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT05136846","Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer","2026-12-31","Carboplatin",{"nctId":68,"briefTitle":69,"date":65,"intervention":47},"NCT03513562","Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations",{"nctId":71,"briefTitle":72,"date":65,"intervention":73},"NCT04049539","Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction","Liposome-encapsulated Daunorubicin-Cytarabine",{"nctId":75,"briefTitle":76,"date":65,"intervention":77},"NCT07166419","Anti-CD19\u002F20\u002F22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia","Autologous Anti-CD19\u002FCD20\u002FCD22 CAR T-cells",{"nctId":79,"briefTitle":80,"date":65,"intervention":81},"NCT04754321","Combining Immunotherapy Salvage Surgery & IORT Tx Persistent\u002FRecurrent Head & Neck Cancer","Pembrolizumab",[83,84,85,86,87,88],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[90,168,196,214,232,256,452,524,640,681,732,764,786,817,839,875,902,920,938,956,981,999,1022,1051,1147,1194,1221,1260,1278,1296,1316,1345,1363,1384,1402,1427,1445,1463,1481,1535,1559,1581,1599,1617,1635,1653,1671,1734,1815,1886,1922,1951,1977,2017,2044,2074,2102,2124,2151,2184,2211,2240,2262,2297,2334,2356,2388,2410,2432,2469,2502,2524,2546,2569,2587,2605,2623,2647,2665,2683,2701,2719,2737,2755,2773,2791,2809,2827,2845,2863,2881,2899,2928,2946,2964,2989,3012,3036,3063,3121,3139,3157,3185,3203,3221,3239,3257,3285,3307,3331,3355,3378,3396,3414,3445,3480,3505,3523,3554,3572,3590,3625,3643,3661,3679,3697,3715,3733,3751,3769,3787,3805,3823,3852,3877,3895,3921,3939,3957,3975,4000,4018,4036,4054,4072,4100,4124,4142,4167,4212,4247,4271,4289,4315,4333,4357,4384,4402,4426,4452,4470,4488,4506,4524],{"intervention":91,"totalTrials":92,"cells":93},"Nicotine Oral Pouch",6,{"EARLY_PHASE1":94,"PHASE1":118,"PHASE2":120,"PHASE3":135,"PHASE4":137,"NA":148},{"trials":95,"activeCount":117},[96,108],{"nctId":97,"briefTitle":98,"status":99,"phases":100,"primaryCompletion":101,"completion":102,"start":103,"enrollment":104,"conditions":105,"interventions":106},"NCT05730439","Examining the Impact of Nicotine Pouches in Rural Ohio and Ohio Appalachia","COMPLETED",[83],"2024-01-30","2024-08-05","2023-05-19",71,[27],[91,91,107],"Smokeless Tobacco",{"nctId":109,"briefTitle":110,"status":99,"phases":111,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":115,"interventions":116},"NCT05236894","Appeal of Nicotine Pouches Versus Cigarettes in the Ohio Appalachia Population",[83],"2023-04-18","2022-03-01",55,[35],[91,91,91,91,91],0,{"trials":119,"activeCount":117},[],{"trials":121,"activeCount":134,"soonestReadout":127},[122],{"nctId":123,"briefTitle":124,"status":125,"phases":126,"primaryCompletion":127,"completion":128,"start":129,"enrollment":130,"conditions":131,"interventions":132},"NCT06315881","Informing Oral Nicotine Pouch Regulations to Promote Public Health","RECRUITING",[85],"2028-01-31","2028-08-31","2025-01-13",160,[27],[133,91,91,91,91,107],"Cigarette",1,{"trials":136,"activeCount":117},[],{"trials":138,"activeCount":134,"soonestReadout":144},[139],{"nctId":140,"briefTitle":141,"status":142,"phases":143,"primaryCompletion":144,"completion":144,"start":145,"enrollment":22,"conditions":146,"interventions":147},"NCT07503925","THRIVE Study: Understanding How Oral Nicotine Pouches Affect Public Health","NOT_YET_RECRUITING",[87],"2027-12-31","2026-07-01",[27],[91,91],{"trials":149,"activeCount":9,"soonestReadout":65},[150,159],{"nctId":151,"briefTitle":152,"status":125,"phases":153,"primaryCompletion":144,"completion":144,"start":154,"enrollment":155,"conditions":156,"interventions":158},"NCT07095140","Studying the Effects of Nicotine Concentration and Flavor on Alcohol Use in Young Adults",[88],"2025-09-03",20,[157],"Alcohol-Related Carcinoma",[91],{"nctId":160,"briefTitle":161,"status":125,"phases":162,"primaryCompletion":65,"completion":65,"start":163,"enrollment":164,"conditions":165,"interventions":166},"NCT07111234","Studying Flavors and Cooling Agents in Oral Nicotine Pouches to Understand User Preferences",[88],"2025-09-15",30,[35],[91,167],"Smoke usual brand cigarette",{"intervention":169,"totalTrials":134,"cells":170},"Reduced Nicotine Content Cigars",{"EARLY_PHASE1":171,"PHASE1":173,"PHASE2":175,"PHASE3":177,"PHASE4":179,"NA":194},{"trials":172,"activeCount":117},[],{"trials":174,"activeCount":117},[],{"trials":176,"activeCount":117},[],{"trials":178,"activeCount":117},[],{"trials":180,"activeCount":134,"soonestReadout":185},[181],{"nctId":182,"briefTitle":183,"status":125,"phases":184,"primaryCompletion":185,"completion":186,"start":187,"enrollment":188,"conditions":189,"interventions":191},"NCT06630728","Addiction Potential of Very Low Nicotine Filtered Little Cigars",[87],"2027-12","2028-01","2025-02-13",50,[190],"Smoking (Tobacco) Addiction",[169,192,193],"Normal nicotine content cigar","Usual brand cigar",{"trials":195,"activeCount":117},[],{"intervention":192,"totalTrials":134,"cells":197},{"EARLY_PHASE1":198,"PHASE1":200,"PHASE2":202,"PHASE3":204,"PHASE4":206,"NA":212},{"trials":199,"activeCount":117},[],{"trials":201,"activeCount":117},[],{"trials":203,"activeCount":117},[],{"trials":205,"activeCount":117},[],{"trials":207,"activeCount":134,"soonestReadout":185},[208],{"nctId":182,"briefTitle":183,"status":125,"phases":209,"primaryCompletion":185,"completion":186,"start":187,"enrollment":188,"conditions":210,"interventions":211},[87],[190],[169,192,193],{"trials":213,"activeCount":117},[],{"intervention":193,"totalTrials":134,"cells":215},{"EARLY_PHASE1":216,"PHASE1":218,"PHASE2":220,"PHASE3":222,"PHASE4":224,"NA":230},{"trials":217,"activeCount":117},[],{"trials":219,"activeCount":117},[],{"trials":221,"activeCount":117},[],{"trials":223,"activeCount":117},[],{"trials":225,"activeCount":134,"soonestReadout":185},[226],{"nctId":182,"briefTitle":183,"status":125,"phases":227,"primaryCompletion":185,"completion":186,"start":187,"enrollment":188,"conditions":228,"interventions":229},[87],[190],[169,192,193],{"trials":231,"activeCount":117},[],{"intervention":233,"totalTrials":134,"cells":234},"BCG Solution",{"EARLY_PHASE1":235,"PHASE1":237,"PHASE2":239,"PHASE3":241,"PHASE4":243,"NA":254},{"trials":236,"activeCount":117},[],{"trials":238,"activeCount":117},[],{"trials":240,"activeCount":117},[],{"trials":242,"activeCount":117},[],{"trials":244,"activeCount":134,"soonestReadout":144},[245],{"nctId":246,"briefTitle":247,"status":125,"phases":248,"primaryCompletion":144,"completion":144,"start":249,"enrollment":250,"conditions":251,"interventions":253},"NCT07474519","Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer",[87],"2026-02-26",40,[252],"Non-Muscle Invasive Bladder Carcinoma",[233,233,233],{"trials":255,"activeCount":117},[],{"intervention":257,"totalTrials":36,"cells":258},"Paclitaxel",{"EARLY_PHASE1":259,"PHASE1":304,"PHASE2":382,"PHASE3":428,"PHASE4":448,"NA":450},{"trials":260,"activeCount":134,"soonestReadout":65},[261],{"nctId":262,"briefTitle":263,"status":125,"phases":264,"primaryCompletion":65,"completion":65,"start":265,"enrollment":266,"conditions":267,"interventions":301},"NCT05415709","Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer",[83],"2022-06-13",45,[268,269,270,271,272,273,274,275,276,277,278,279,280,281,282,283,284,285,286,287,288,289,290,291,292,293,294,295,296,297,298,299,300],"Fallopian Tube Endometrioid Adenocarcinoma","Fallopian Tube Mucinous Adenocarcinoma","Fallopian Tube Serous Adenocarcinoma","Ovarian Endometrioid Adenocarcinoma","Ovarian Mucinous Adenocarcinoma","Ovarian Serous Adenocarcinoma","Primary Peritoneal Endometrioid Adenocarcinoma","Primary Peritoneal Serous Adenocarcinoma","Stage III Fallopian Tube Cancer AJCC v8","Stage III Ovarian Cancer AJCC v8","Stage III Primary Peritoneal Cancer AJCC v8","Stage IIIA Fallopian Tube Cancer AJCC v8","Stage IIIA Ovarian Cancer AJCC v8","Stage IIIA Primary Peritoneal Cancer AJCC v8","Stage IIIA1 Fallopian Tube Cancer AJCC v8","Stage IIIA1 Ovarian Cancer AJCC v8","Stage IIIA2 Fallopian Tube Cancer AJCC v8","Stage IIIA2 Ovarian Cancer AJCC v8","Stage IIIB Fallopian Tube Cancer AJCC v8","Stage IIIB Ovarian Cancer AJCC v8","Stage IIIB Primary Peritoneal Cancer AJCC v8","Stage IIIC Fallopian Tube Cancer AJCC v8","Stage IIIC Ovarian Cancer AJCC v8","Stage IIIC Primary Peritoneal Cancer AJCC v8","Stage IV Fallopian Tube Cancer AJCC v8","Stage IV Ovarian Cancer AJCC v8","Stage IV Primary Peritoneal Cancer AJCC v8","Stage IVA Fallopian Tube Cancer AJCC v8","Stage IVA Ovarian Cancer AJCC v8","Stage IVA Primary Peritoneal Cancer AJCC v8","Stage IVB Fallopian Tube Cancer AJCC v8","Stage IVB Ovarian Cancer AJCC v8","Stage IVB Primary Peritoneal Cancer AJCC v8",[66,302,303,257],"Cisplatin","Hyperthermic Intraperitoneal Chemotherapy",{"trials":305,"activeCount":134,"soonestReadout":65},[306,317,335,345,373],{"nctId":307,"briefTitle":308,"status":309,"phases":310,"start":311,"conditions":312,"interventions":314},"NCT00004173","Oxaliplatin and Paclitaxel in Treating Patients With Metastatic or Unresectable Cancer","UNKNOWN",[84],"1999-10",[313],"Unspecified Adult Solid Tumor, Protocol Specific",[315,316],"oxaliplatin","paclitaxel",{"nctId":63,"briefTitle":64,"status":125,"phases":318,"primaryCompletion":65,"completion":65,"start":319,"enrollment":320,"conditions":321,"interventions":331},[84],"2021-12-06",28,[322,323,324,325,326,327,328,329,330],"Locally Advanced Lung Non-Small Cell Carcinoma","Stage II Lung Cancer AJCC v8","Stage IIA Lung Cancer AJCC v8","Stage IIB Lung Cancer AJCC v8","Stage III Lung Cancer AJCC v8","Stage IIIA Lung Cancer AJCC v8","Stage IIIB Lung Cancer AJCC v8","Stage IIIC Lung Cancer AJCC v8","Unresectable Lung Non-Small Cell Carcinoma",[66,332,257,333,334],"Durvalumab","Papaverine","Pemetrexed",{"nctId":336,"briefTitle":337,"status":99,"phases":338,"primaryCompletion":339,"completion":340,"start":341,"enrollment":155,"conditions":342,"interventions":344},"NCT03535701","Ketogenic Diet and Chemotherapy in Affecting Recurrence in Patients With Stage IV Breast Cancer",[84],"2020-03-01","2020-05-01","2017-10-20",[343],"Stage IV Breast Cancer AJCC v6 and v7",[257],{"nctId":346,"briefTitle":347,"status":99,"phases":348,"primaryCompletion":349,"completion":350,"start":351,"enrollment":36,"conditions":352,"interventions":370},"NCT04205903","Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer",[84],"2024-06-19","2024-12-18","2020-12-11",[29,353,354,18,355,356,21,357,358,359,360,361,362,363,364,365,366,367,368,369],"Anatomic Stage IA Breast Cancer AJCC v8","Anatomic Stage IB Breast Cancer AJCC v8","Anatomic Stage IIA Breast Cancer AJCC v8","Anatomic Stage IIB Breast Cancer AJCC v8","Anatomic Stage IIIA Breast Cancer AJCC v8","Anatomic Stage IIIB Breast Cancer AJCC v8","Anatomic Stage IIIC Breast Cancer AJCC v8","Prognostic Stage I Breast Cancer AJCC v8","Prognostic Stage IA Breast Cancer AJCC v8","Prognostic Stage IB Breast Cancer AJCC v8","Prognostic Stage II Breast Cancer AJCC v8","Prognostic Stage IIA Breast Cancer AJCC v8","Prognostic Stage IIB Breast Cancer AJCC v8","Prognostic Stage III Breast Cancer AJCC v8","Prognostic Stage IIIA Breast Cancer AJCC v8","Prognostic Stage IIIB Breast Cancer AJCC v8","Prognostic Stage IIIC Breast Cancer AJCC v8",[371,372,257],"Nilotinib","Nilotinib Hydrochloride Monohydrate",{"nctId":374,"briefTitle":375,"status":309,"phases":376,"start":377,"conditions":378,"interventions":379},"NCT00009932","Combination Chemotherapy in Treating Patients With Solid Tumors",[84],"2001-01",[313],[380,381,316],"cisplatin","fenretinide",{"trials":383,"activeCount":9,"soonestReadout":65},[384,394,404,418],{"nctId":385,"briefTitle":386,"status":387,"phases":388,"primaryCompletion":389,"completion":389,"start":390,"enrollment":36,"conditions":391,"interventions":393},"NCT00566540","Ph 2 Intensification Regimen for Previously Untreated, Resectable, Advanced Squamous Cell Cancer","TERMINATED",[85],"2010-02-25","2007-12-11",[392],"Head and Neck Cancer",[302,257],{"nctId":395,"briefTitle":396,"status":125,"phases":397,"primaryCompletion":144,"completion":144,"start":398,"enrollment":399,"conditions":400,"interventions":402},"NCT07529483","Endoscopic Ultrasound-Guided Chemoablation for the Treatment of Pancreatic Cystic Neoplasms",[85],"2026-05-12",35,[401],"Pancreatic Cystic Neoplasm",[403,257],"Gemcitabine Hydrochloride",{"nctId":405,"briefTitle":406,"status":387,"phases":407,"primaryCompletion":408,"completion":409,"start":410,"enrollment":411,"conditions":412,"interventions":416},"NCT00201734","Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary",[84,85],"2007-11","2013-06","2005-06",57,[413,414,415],"Tumors","Unknown Primary Tumors","Adenocarcinoma",[417,66,257],"Capecitabine",{"nctId":419,"briefTitle":420,"status":125,"phases":421,"primaryCompletion":65,"completion":65,"start":422,"enrollment":266,"conditions":423,"interventions":427},"NCT06323460","Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer",[85],"2024-03-21",[424,425,426],"Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Oropharyngeal Squamous Cell Carcinoma",[66,302,257],{"trials":429,"activeCount":117},[430],{"nctId":431,"briefTitle":432,"status":99,"phases":433,"primaryCompletion":434,"completion":434,"start":435,"enrollment":436,"conditions":437,"interventions":442},"NCT04862585","Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel",[85,86],"2024-06-21","2021-10-07",130,[438,29,353,354,18,355,356,21,357,358,359,439,32,440,360,361,362,363,364,365,366,367,368,369,441],"Anatomic Stage 0 Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Prognostic Stage 0 Breast Cancer AJCC v8","Prognostic Stage IV Breast Cancer AJCC v8",[443,444,445,446,257,447],"Cimetidine","Dexamethasone","Diphenhydramine","Famotidine","Ranitidine",{"trials":449,"activeCount":117},[],{"trials":451,"activeCount":117},[],{"intervention":66,"totalTrials":453,"cells":454},7,{"EARLY_PHASE1":455,"PHASE1":461,"PHASE2":467,"PHASE3":518,"PHASE4":520,"NA":522},{"trials":456,"activeCount":134,"soonestReadout":65},[457],{"nctId":262,"briefTitle":263,"status":125,"phases":458,"primaryCompletion":65,"completion":65,"start":265,"enrollment":266,"conditions":459,"interventions":460},[83],[268,269,270,271,272,273,274,275,276,277,278,279,280,281,282,283,284,285,286,287,288,289,290,291,292,293,294,295,296,297,298,299,300],[66,302,303,257],{"trials":462,"activeCount":134,"soonestReadout":65},[463],{"nctId":63,"briefTitle":64,"status":125,"phases":464,"primaryCompletion":65,"completion":65,"start":319,"enrollment":320,"conditions":465,"interventions":466},[84],[322,323,324,325,326,327,328,329,330],[66,332,257,333,334],{"trials":468,"activeCount":134,"soonestReadout":65},[469,483,496,500,504],{"nctId":470,"briefTitle":471,"status":99,"phases":472,"primaryCompletion":473,"completion":474,"start":475,"enrollment":476,"conditions":477,"interventions":478},"NCT00675259","Phase II NCT (Neoadjuvant Chemotherapy) w\u002F Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast Cancer",[85],"2011-05","2014-03","2008-07",33,[15],[479,480,481,482],"bevacizumab","carboplatin","nab-paclitaxel","Adjuvant chemotherapy",{"nctId":484,"briefTitle":485,"status":99,"phases":486,"primaryCompletion":487,"completion":488,"start":489,"enrollment":490,"conditions":491,"interventions":494},"NCT00362817","Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases",[84,85],"2008-01","2008-02","2004-10",17,[492,493],"Brain Tumor","Brain Metastases",[480,495],"temozolomide",{"nctId":405,"briefTitle":406,"status":387,"phases":497,"primaryCompletion":408,"completion":409,"start":410,"enrollment":411,"conditions":498,"interventions":499},[84,85],[413,414,415],[417,66,257],{"nctId":419,"briefTitle":420,"status":125,"phases":501,"primaryCompletion":65,"completion":65,"start":422,"enrollment":266,"conditions":502,"interventions":503},[85],[424,425,426],[66,302,257],{"nctId":505,"briefTitle":506,"status":99,"phases":507,"primaryCompletion":508,"completion":509,"start":510,"enrollment":266,"conditions":511,"interventions":515},"NCT00267696","Study of Gemcitabine\u002FCarboplatin\u002FBevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer",[85],"2013-09","2013-12","2005-11",[512,513,514],"Ovarian Cancer","Fallopian Tube Cancer","Peritoneal Cancer",[516,517,66],"Bevacizumab","Gemcitabine",{"trials":519,"activeCount":117},[],{"trials":521,"activeCount":117},[],{"trials":523,"activeCount":117},[],{"intervention":380,"totalTrials":525,"cells":526},8,{"EARLY_PHASE1":527,"PHASE1":533,"PHASE2":609,"PHASE3":634,"PHASE4":636,"NA":638},{"trials":528,"activeCount":134,"soonestReadout":65},[529],{"nctId":262,"briefTitle":263,"status":125,"phases":530,"primaryCompletion":65,"completion":65,"start":265,"enrollment":266,"conditions":531,"interventions":532},[83],[268,269,270,271,272,273,274,275,276,277,278,279,280,281,282,283,284,285,286,287,288,289,290,291,292,293,294,295,296,297,298,299,300],[66,302,303,257],{"trials":534,"activeCount":117},[535,583,595,605],{"nctId":536,"briefTitle":537,"status":99,"phases":538,"primaryCompletion":539,"completion":539,"start":540,"enrollment":541,"conditions":542,"interventions":580},"NCT02035527","Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck",[84],"2017-04-20","2014-04-14",3,[543,544,545,546,547,548,549,550,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,576,577,578,579],"Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma","Recurrent Metastatic Squamous Neck Cancer With Occult Primary","Recurrent Salivary Gland Cancer","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Nasopharynx","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Recurrent Verrucous Carcinoma of the Larynx","Recurrent Verrucous Carcinoma of the Oral Cavity","Salivary Gland Squamous Cell Carcinoma","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Nasopharynx","Stage IVA Salivary Gland Cancer","Stage IVA Squamous Cell Carcinoma of the Larynx","Stage IVA Oral Cavity Squamous Cell Carcinoma","Stage IVA Squamous Cell Carcinoma of the Oropharynx","Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVA Verrucous Carcinoma of the Larynx","Stage IVA Verrucous Carcinoma of the Oral Cavity","Stage IVB Salivary Gland Cancer","Stage IVB Squamous Cell Carcinoma of the Larynx","Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVB Squamous Cell Carcinoma of the Oropharynx","Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVB Verrucous Carcinoma of the Larynx","Stage IVB Verrucous Carcinoma of the Oral Cavity","Stage IVC Salivary Gland Cancer","Stage IVC Squamous Cell Carcinoma of the Larynx","Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVC Squamous Cell Carcinoma of the Oropharynx","Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVC Verrucous Carcinoma of the Larynx","Stage IVC Verrucous Carcinoma of the Oral Cavity","Tongue Cancer","Untreated Metastatic Squamous Neck Cancer With Occult Primary",[581,380,582],"sorafenib tosylate","docetaxel",{"nctId":584,"briefTitle":585,"status":99,"phases":586,"primaryCompletion":587,"completion":587,"start":588,"enrollment":589,"conditions":590,"interventions":593},"NCT01064921","Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma",[84],"2017-11-08","2010-01-19",27,[591,592],"Stage III Squamous Cell Carcinoma of the Oropharynx","Stage IV Squamous Cell Carcinoma of the Oropharynx",[594,380],"vorinostat",{"nctId":596,"briefTitle":597,"status":99,"phases":598,"completion":599,"start":600,"conditions":601,"interventions":602},"NCT00006000","SU5416, Irinotecan, and Cisplatin in Treating Patients With Advanced Solid Tumors",[84],"2004-03","2000-08",[313],[380,603,604],"irinotecan hydrochloride","semaxanib",{"nctId":374,"briefTitle":375,"status":309,"phases":606,"start":377,"conditions":607,"interventions":608},[84],[313],[380,381,316],{"trials":610,"activeCount":134,"soonestReadout":65},[611,615,630],{"nctId":385,"briefTitle":386,"status":387,"phases":612,"primaryCompletion":389,"completion":389,"start":390,"enrollment":36,"conditions":613,"interventions":614},[85],[392],[302,257],{"nctId":616,"briefTitle":617,"status":99,"phases":618,"primaryCompletion":619,"completion":619,"start":620,"enrollment":621,"conditions":622,"interventions":628},"NCT02262325","Hypofractionated Boost Before Chemoradiation for Patients With Stage II-III Non-small Cell Lung Cancer Unsuitable for Surgery",[85],"2024-04-15","2015-06-08",21,[623,624,625,626,627],"Recurrent Non-small Cell Lung Cancer","Stage IIA Non-small Cell Lung Cancer","Stage IIB Non-small Cell Lung Cancer","Stage IIIA Non-small Cell Lung Cancer","Stage IIIB Non-small Cell Lung Cancer",[380,629],"etoposide",{"nctId":419,"briefTitle":420,"status":125,"phases":631,"primaryCompletion":65,"completion":65,"start":422,"enrollment":266,"conditions":632,"interventions":633},[85],[424,425,426],[66,302,257],{"trials":635,"activeCount":117},[],{"trials":637,"activeCount":117},[],{"trials":639,"activeCount":117},[],{"intervention":47,"totalTrials":541,"cells":641},{"EARLY_PHASE1":642,"PHASE1":644,"PHASE2":657,"PHASE3":675,"PHASE4":677,"NA":679},{"trials":643,"activeCount":117},[],{"trials":645,"activeCount":117},[646],{"nctId":647,"briefTitle":648,"status":99,"phases":649,"primaryCompletion":650,"completion":651,"start":652,"enrollment":19,"conditions":653,"interventions":655},"NCT03525925","Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors",[84],"2020-02-20","2022-07-31","2018-07-18",[654],"Metastatic Malignant Solid Neoplasm",[47,656],"Nivolumab",{"trials":658,"activeCount":9,"soonestReadout":46},[659,667],{"nctId":44,"briefTitle":45,"status":660,"phases":661,"primaryCompletion":46,"completion":46,"start":662,"enrollment":663,"conditions":664,"interventions":666},"ACTIVE_NOT_RECRUITING",[85],"2016-12-20",18,[665],"Classical Hodgkin Lymphoma",[47,656],{"nctId":68,"briefTitle":69,"status":660,"phases":668,"primaryCompletion":65,"completion":65,"start":669,"enrollment":320,"conditions":670,"interventions":673},[85],"2019-03-26",[671,672],"Chronic Lymphocytic Leukemia","Ibrutinib Resistance",[47,674],"Venetoclax",{"trials":676,"activeCount":117},[],{"trials":678,"activeCount":117},[],{"trials":680,"activeCount":117},[],{"intervention":674,"totalTrials":541,"cells":682},{"EARLY_PHASE1":683,"PHASE1":685,"PHASE2":687,"PHASE3":726,"PHASE4":728,"NA":730},{"trials":684,"activeCount":117},[],{"trials":686,"activeCount":117},[],{"trials":688,"activeCount":9,"soonestReadout":56},[689,714,722],{"nctId":690,"briefTitle":691,"status":99,"phases":692,"primaryCompletion":693,"completion":693,"start":694,"enrollment":695,"conditions":696,"interventions":709},"NCT03583424","Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma",[84,85],"2021-09-30","2018-09-10",19,[697,698,699,700,701,702,703,704,705,706,707,708],"Hematopoietic Cell Transplantation Recipient","Recurrent Diffuse Large B-Cell Lymphoma","Recurrent Grade 1 Follicular Lymphoma","Recurrent Grade 2 Follicular Lymphoma","Recurrent Grade 3 Follicular Lymphoma","Recurrent Marginal Zone Lymphoma","Recurrent Non-Hodgkin Lymphoma","Refractory Diffuse Large B-Cell Lymphoma","Refractory Follicular Lymphoma","Refractory Marginal Zone Lymphoma","Refractory Non-Hodgkin Lymphoma","Refractory Transformed Indolent Non-Hodgkin Lymphoma",[710,711,712,713,674],"Carmustine","Cytarabine","Etoposide","Melphalan",{"nctId":54,"briefTitle":55,"status":125,"phases":715,"primaryCompletion":56,"completion":56,"start":716,"enrollment":717,"conditions":718,"interventions":720},[85],"2022-09-13",52,[671,719],"Small Lymphocytic Lymphoma",[57,721,674],"Obinutuzumab",{"nctId":68,"briefTitle":69,"status":660,"phases":723,"primaryCompletion":65,"completion":65,"start":669,"enrollment":320,"conditions":724,"interventions":725},[85],[671,672],[47,674],{"trials":727,"activeCount":117},[],{"trials":729,"activeCount":117},[],{"trials":731,"activeCount":117},[],{"intervention":733,"totalTrials":9,"cells":734},"Minoxidil",{"EARLY_PHASE1":735,"PHASE1":746,"PHASE2":748,"PHASE3":758,"PHASE4":760,"NA":762},{"trials":736,"activeCount":134,"soonestReadout":741},[737],{"nctId":738,"briefTitle":739,"status":125,"phases":740,"primaryCompletion":741,"completion":144,"start":742,"enrollment":188,"conditions":743,"interventions":745},"NCT05417308","Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer",[83],"2027-12-01","2023-03-01",[29,353,354,18,355,356,21,357,358,359,439,744,360,361,362,363,364,365,366,367,368,369,441],"Endocrine Therapy-Induced Alopecia",[733,733],{"trials":747,"activeCount":117},[],{"trials":749,"activeCount":134,"soonestReadout":144},[750],{"nctId":751,"briefTitle":752,"status":142,"phases":753,"primaryCompletion":144,"completion":144,"start":754,"enrollment":188,"conditions":755,"interventions":757},"NCT07594678","Minoxidil With or Without Low-Level Red-Light Therapy for Improving Chemotherapy-Induced Alopecia in Breast Cancer Patients",[85],"2026-07-02",[29,18,21,439,756],"Chemotherapy-Induced Alopecia",[733],{"trials":759,"activeCount":117},[],{"trials":761,"activeCount":117},[],{"trials":763,"activeCount":117},[],{"intervention":656,"totalTrials":9,"cells":765},{"EARLY_PHASE1":766,"PHASE1":768,"PHASE2":774,"PHASE3":780,"PHASE4":782,"NA":784},{"trials":767,"activeCount":117},[],{"trials":769,"activeCount":117},[770],{"nctId":647,"briefTitle":648,"status":99,"phases":771,"primaryCompletion":650,"completion":651,"start":652,"enrollment":19,"conditions":772,"interventions":773},[84],[654],[47,656],{"trials":775,"activeCount":134,"soonestReadout":46},[776],{"nctId":44,"briefTitle":45,"status":660,"phases":777,"primaryCompletion":46,"completion":46,"start":662,"enrollment":663,"conditions":778,"interventions":779},[85],[665],[47,656],{"trials":781,"activeCount":117},[],{"trials":783,"activeCount":117},[],{"trials":785,"activeCount":117},[],{"intervention":133,"totalTrials":9,"cells":787},{"EARLY_PHASE1":788,"PHASE1":803,"PHASE2":805,"PHASE3":811,"PHASE4":813,"NA":815},{"trials":789,"activeCount":117},[790],{"nctId":791,"briefTitle":792,"status":99,"phases":793,"primaryCompletion":794,"completion":795,"start":796,"enrollment":797,"conditions":798,"interventions":801},"NCT03691350","Bronchoscopy in Determining the Effect of E-Cigarette Smoking on Biomarkers in the Lungs",[83],"2023-10-23","2024-03-10","2018-09-17",66,[799,800],"Cigarette Smoker","Current Every Day Smoker",[133,802],"Nicotine Replacement",{"trials":804,"activeCount":117},[],{"trials":806,"activeCount":134,"soonestReadout":127},[807],{"nctId":123,"briefTitle":124,"status":125,"phases":808,"primaryCompletion":127,"completion":128,"start":129,"enrollment":130,"conditions":809,"interventions":810},[85],[27],[133,91,91,91,91,107],{"trials":812,"activeCount":117},[],{"trials":814,"activeCount":117},[],{"trials":816,"activeCount":117},[],{"intervention":107,"totalTrials":9,"cells":818},{"EARLY_PHASE1":819,"PHASE1":825,"PHASE2":827,"PHASE3":833,"PHASE4":835,"NA":837},{"trials":820,"activeCount":117},[821],{"nctId":97,"briefTitle":98,"status":99,"phases":822,"primaryCompletion":101,"completion":102,"start":103,"enrollment":104,"conditions":823,"interventions":824},[83],[27],[91,91,107],{"trials":826,"activeCount":117},[],{"trials":828,"activeCount":134,"soonestReadout":127},[829],{"nctId":123,"briefTitle":124,"status":125,"phases":830,"primaryCompletion":127,"completion":128,"start":129,"enrollment":130,"conditions":831,"interventions":832},[85],[27],[133,91,91,91,91,107],{"trials":834,"activeCount":117},[],{"trials":836,"activeCount":117},[],{"trials":838,"activeCount":117},[],{"intervention":73,"totalTrials":9,"cells":840},{"EARLY_PHASE1":841,"PHASE1":843,"PHASE2":845,"PHASE3":869,"PHASE4":871,"NA":873},{"trials":842,"activeCount":117},[],{"trials":844,"activeCount":117},[],{"trials":846,"activeCount":134,"soonestReadout":65},[847,855],{"nctId":71,"briefTitle":72,"status":125,"phases":848,"primaryCompletion":65,"completion":65,"start":849,"enrollment":320,"conditions":850,"interventions":854},[84,85],"2021-01-29",[851,852,853],"Blasts More Than 5 Percent of Bone Marrow Nucleated Cells","Persistent Disease","Refractory Acute Myeloid Leukemia",[73],{"nctId":856,"briefTitle":857,"status":387,"phases":858,"primaryCompletion":859,"completion":859,"start":860,"enrollment":33,"conditions":861,"interventions":867},"NCT03878199","Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms",[84,85],"2025-02-27","2019-02-20",[862,863,864,865,866],"Essential Thrombocythemia","Myelofibrosis","Myeloproliferative Neoplasm","Polycythemia Vera","Secondary Acute Myeloid Leukemia",[73,868],"Ruxolitinib",{"trials":870,"activeCount":117},[],{"trials":872,"activeCount":117},[],{"trials":874,"activeCount":117},[],{"intervention":876,"totalTrials":134,"cells":877},"Leuprolide",{"EARLY_PHASE1":878,"PHASE1":880,"PHASE2":882,"PHASE3":896,"PHASE4":898,"NA":900},{"trials":879,"activeCount":117},[],{"trials":881,"activeCount":117},[],{"trials":883,"activeCount":134,"soonestReadout":144},[884],{"nctId":885,"briefTitle":886,"status":125,"phases":887,"primaryCompletion":144,"completion":144,"start":888,"enrollment":889,"conditions":890,"interventions":894},"NCT06330805","Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer",[85],"2024-08-12",70,[891,892,893],"Prostate Adenocarcinoma","Stage IIB Prostate Cancer AJCC v8","Stage IIC Prostate Cancer AJCC v8",[876,895],"Relugolix",{"trials":897,"activeCount":117},[],{"trials":899,"activeCount":117},[],{"trials":901,"activeCount":117},[],{"intervention":895,"totalTrials":134,"cells":903},{"EARLY_PHASE1":904,"PHASE1":906,"PHASE2":908,"PHASE3":914,"PHASE4":916,"NA":918},{"trials":905,"activeCount":117},[],{"trials":907,"activeCount":117},[],{"trials":909,"activeCount":134,"soonestReadout":144},[910],{"nctId":885,"briefTitle":886,"status":125,"phases":911,"primaryCompletion":144,"completion":144,"start":888,"enrollment":889,"conditions":912,"interventions":913},[85],[891,892,893],[876,895],{"trials":915,"activeCount":117},[],{"trials":917,"activeCount":117},[],{"trials":919,"activeCount":117},[],{"intervention":57,"totalTrials":134,"cells":921},{"EARLY_PHASE1":922,"PHASE1":924,"PHASE2":926,"PHASE3":932,"PHASE4":934,"NA":936},{"trials":923,"activeCount":117},[],{"trials":925,"activeCount":117},[],{"trials":927,"activeCount":134,"soonestReadout":56},[928],{"nctId":54,"briefTitle":55,"status":125,"phases":929,"primaryCompletion":56,"completion":56,"start":716,"enrollment":717,"conditions":930,"interventions":931},[85],[671,719],[57,721,674],{"trials":933,"activeCount":117},[],{"trials":935,"activeCount":117},[],{"trials":937,"activeCount":117},[],{"intervention":721,"totalTrials":134,"cells":939},{"EARLY_PHASE1":940,"PHASE1":942,"PHASE2":944,"PHASE3":950,"PHASE4":952,"NA":954},{"trials":941,"activeCount":117},[],{"trials":943,"activeCount":117},[],{"trials":945,"activeCount":134,"soonestReadout":56},[946],{"nctId":54,"briefTitle":55,"status":125,"phases":947,"primaryCompletion":56,"completion":56,"start":716,"enrollment":717,"conditions":948,"interventions":949},[85],[671,719],[57,721,674],{"trials":951,"activeCount":117},[],{"trials":953,"activeCount":117},[],{"trials":955,"activeCount":117},[],{"intervention":957,"totalTrials":134,"cells":958},"Neoadjuvant Chemotherapy",{"EARLY_PHASE1":959,"PHASE1":961,"PHASE2":963,"PHASE3":975,"PHASE4":977,"NA":979},{"trials":960,"activeCount":117},[],{"trials":962,"activeCount":117},[],{"trials":964,"activeCount":134,"soonestReadout":144},[965],{"nctId":966,"briefTitle":967,"status":142,"phases":968,"primaryCompletion":144,"completion":144,"start":969,"enrollment":970,"conditions":971,"interventions":974},"NCT07217990","Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer",[84,85],"2026-04-15",84,[15,972,973],"HER2-positive Breast Cancer","Triple Negative Breast Cancer",[957],{"trials":976,"activeCount":117},[],{"trials":978,"activeCount":117},[],{"trials":980,"activeCount":117},[],{"intervention":403,"totalTrials":134,"cells":982},{"EARLY_PHASE1":983,"PHASE1":985,"PHASE2":987,"PHASE3":993,"PHASE4":995,"NA":997},{"trials":984,"activeCount":117},[],{"trials":986,"activeCount":117},[],{"trials":988,"activeCount":134,"soonestReadout":144},[989],{"nctId":395,"briefTitle":396,"status":125,"phases":990,"primaryCompletion":144,"completion":144,"start":398,"enrollment":399,"conditions":991,"interventions":992},[85],[401],[403,257],{"trials":994,"activeCount":117},[],{"trials":996,"activeCount":117},[],{"trials":998,"activeCount":117},[],{"intervention":61,"totalTrials":134,"cells":1000},{"EARLY_PHASE1":1001,"PHASE1":1003,"PHASE2":1005,"PHASE3":1016,"PHASE4":1018,"NA":1020},{"trials":1002,"activeCount":117},[],{"trials":1004,"activeCount":117},[],{"trials":1006,"activeCount":134,"soonestReadout":56},[1007],{"nctId":59,"briefTitle":60,"status":125,"phases":1008,"primaryCompletion":56,"completion":56,"start":1009,"enrollment":1010,"conditions":1011,"interventions":1015},[85],"2023-12-19",100,[1012,1013,1014],"Cutaneous Melanoma","Merkel Cell Carcinoma","Skin Squamous Cell Carcinoma",[61],{"trials":1017,"activeCount":117},[],{"trials":1019,"activeCount":117},[],{"trials":1021,"activeCount":117},[],{"intervention":1023,"totalTrials":134,"cells":1024},"Prasterone",{"EARLY_PHASE1":1025,"PHASE1":1027,"PHASE2":1029,"PHASE3":1045,"PHASE4":1047,"NA":1049},{"trials":1026,"activeCount":117},[],{"trials":1028,"activeCount":117},[],{"trials":1030,"activeCount":134,"soonestReadout":65},[1031],{"nctId":1032,"briefTitle":1033,"status":125,"phases":1034,"primaryCompletion":65,"completion":65,"start":1035,"enrollment":1036,"conditions":1037,"interventions":1044},"NCT07407647","Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer",[85],"2026-03-12",25,[1038,1039,1040,1041,1042,1043],"Anal Carcinoma","Cervical Carcinoma","Malignant Female Reproductive System Neoplasm","Rectal Carcinoma","Vaginal Carcinoma","Vulvar Carcinoma",[1023],{"trials":1046,"activeCount":117},[],{"trials":1048,"activeCount":117},[],{"trials":1050,"activeCount":117},[],{"intervention":1052,"totalTrials":1053,"cells":1054},"Cyclophosphamide",5,{"EARLY_PHASE1":1055,"PHASE1":1057,"PHASE2":1079,"PHASE3":1141,"PHASE4":1143,"NA":1145},{"trials":1056,"activeCount":117},[],{"trials":1058,"activeCount":134,"soonestReadout":65},[1059],{"nctId":75,"briefTitle":76,"status":125,"phases":1060,"primaryCompletion":65,"completion":65,"start":1061,"enrollment":1062,"conditions":1063,"interventions":1077},[84],"2026-01-14",24,[1064,1065,1066,1067,1068,1069,703,1070,1071,1072,1073,1074,1075,707,1076],"Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive","Recurrent Acute Lymphoblastic Leukemia","Recurrent Chronic Lymphocytic Leukemia","Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive","Recurrent Indolent Non-Hodgkin Lymphoma","Recurrent Lymphoblastic Lymphoma","Recurrent Transformed Chronic Lymphocytic Leukemia","Refractory Acute Lymphoblastic Leukemia","Refractory Chronic Lymphocytic Leukemia","Refractory Chronic Myeloid Leukemia, BCR-ABL1 Positive","Refractory Indolent Non-Hodgkin Lymphoma","Refractory Lymphoblastic Lymphoma","Refractory Transformed Chronic Lymphocytic Leukemia",[77,1052,1078],"Fludarabine",{"trials":1080,"activeCount":117},[1081,1105,1118,1130],{"nctId":1082,"briefTitle":1083,"status":309,"phases":1084,"primaryCompletion":1085,"start":1086,"enrollment":1087,"conditions":1088,"interventions":1090},"NCT01005758","Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",[85],"2013-01","2009-01",180,[1089],"Leukemia",[1091,1092,1093,1094,1095,1096,1097,1098,1099,1100,1101,1102,1103,1104],"cyclophosphamide","cytarabine","dexamethasone","doxorubicin hydrochloride","etoposide phosphate","hydrocortisone sodium succinate","imatinib mesylate","mercaptopurine","methotrexate","methylprednisolone","pegaspargase","prednisolone","prednisone","vincristine sulfate",{"nctId":1106,"briefTitle":1107,"status":1108,"phases":1109,"primaryCompletion":1110,"completion":1110,"start":1111,"enrollment":117,"conditions":1112,"interventions":1114},"NCT00983944","Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma","WITHDRAWN",[85],"2011-04-25","2009-09",[1113],"Lymphoma",[1115,1116,1117,1091,1094,629,1103,1104],"bleomycin sulfate","rituximab","EPOCH regimen",{"nctId":1119,"briefTitle":1120,"status":99,"phases":1121,"primaryCompletion":1122,"completion":1123,"start":1124,"enrollment":320,"conditions":1125,"interventions":1127},"NCT00201721","Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia",[85],"2006-07","2006-09","2002-07",[1126],"B-Chronic Lymphocytic Leukemia",[1128,1129,1052],"Pentostatin","Rituximab",{"nctId":1131,"briefTitle":1132,"status":99,"phases":1133,"primaryCompletion":1134,"completion":1135,"start":489,"enrollment":1136,"conditions":1137,"interventions":1138},"NCT00201708","Dose-Dense Docetaxel Before or After Doxorubicin\u002FCyclophosphamide in Axillary Node-Positive Breast Cancer",[85],"2006-12","2014-02",56,[15],[1139,1140,1052],"Docetaxel","Doxorubicin",{"trials":1142,"activeCount":117},[],{"trials":1144,"activeCount":117},[],{"trials":1146,"activeCount":117},[],{"intervention":1078,"totalTrials":541,"cells":1148},{"EARLY_PHASE1":1149,"PHASE1":1151,"PHASE2":1174,"PHASE3":1188,"PHASE4":1190,"NA":1192},{"trials":1150,"activeCount":117},[],{"trials":1152,"activeCount":134,"soonestReadout":65},[1153,1170],{"nctId":1154,"briefTitle":1155,"status":99,"phases":1156,"primaryCompletion":1157,"completion":1158,"start":1159,"enrollment":16,"conditions":1160,"interventions":1166},"NCT02512497","Romidepsin Maintenance After Allogeneic Stem Cell Transplantation",[84],"2023-10-06","2025-06-18","2017-12-08",[1161,1162,1163,1164,1165],"Cutaneous T-cell Lymphoma","T-Prolymphocytic Leukemia","T-Large Granulocytic Leukemia","T-Lymphoblastic Leukemia\u002FLymphoma","Peripheral T-Cell Lymphoma",[1167,1168,1078,1169],"Romidepsin","Busulfan","Thymoglobulin",{"nctId":75,"briefTitle":76,"status":125,"phases":1171,"primaryCompletion":65,"completion":65,"start":1061,"enrollment":1062,"conditions":1172,"interventions":1173},[84],[1064,1065,1066,1067,1068,1069,703,1070,1071,1072,1073,1074,1075,707,1076],[77,1052,1078],{"trials":1175,"activeCount":117},[1176],{"nctId":1177,"briefTitle":1178,"status":99,"phases":1179,"primaryCompletion":1180,"completion":1181,"start":1182,"enrollment":525,"conditions":1183,"interventions":1186},"NCT00143065","Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[85],"2007-02","2009-07","2005-08",[1184,1185],"Lymphoma, Small Lymphocytic","Lymphocytic Leukemia, Chronic",[1078,1129,1187],"Alemtuzumab",{"trials":1189,"activeCount":117},[],{"trials":1191,"activeCount":117},[],{"trials":1193,"activeCount":117},[],{"intervention":334,"totalTrials":9,"cells":1195},{"EARLY_PHASE1":1196,"PHASE1":1198,"PHASE2":1204,"PHASE3":1215,"PHASE4":1217,"NA":1219},{"trials":1197,"activeCount":117},[],{"trials":1199,"activeCount":134,"soonestReadout":65},[1200],{"nctId":63,"briefTitle":64,"status":125,"phases":1201,"primaryCompletion":65,"completion":65,"start":319,"enrollment":320,"conditions":1202,"interventions":1203},[84],[322,323,324,325,326,327,328,329,330],[66,332,257,333,334],{"trials":1205,"activeCount":117},[1206],{"nctId":1207,"briefTitle":1208,"status":99,"phases":1209,"primaryCompletion":1210,"completion":1211,"start":1212,"enrollment":1053,"conditions":1213,"interventions":1214},"NCT00293579","Pemetrexed Chemotherapy in Poor-Risk Patients With Advanced Head and Neck Cancer",[85],"2008-05","2008-11","2006-02",[392],[334],{"trials":1216,"activeCount":117},[],{"trials":1218,"activeCount":117},[],{"trials":1220,"activeCount":117},[],{"intervention":81,"totalTrials":9,"cells":1222},{"EARLY_PHASE1":1223,"PHASE1":1225,"PHASE2":1238,"PHASE3":1254,"PHASE4":1256,"NA":1258},{"trials":1224,"activeCount":117},[],{"trials":1226,"activeCount":134,"soonestReadout":65},[1227],{"nctId":79,"briefTitle":80,"status":125,"phases":1228,"primaryCompletion":65,"completion":65,"start":1229,"enrollment":266,"conditions":1230,"interventions":1237},[84],"2022-05-12",[1231,1232,1233,1234,1235,1236],"Head and Neck Carcinoma of Unknown Primary","Locally Recurrent Head and Neck Squamous Cell Carcinoma","Recurrent Laryngeal Squamous Cell Carcinoma","Recurrent Oral Cavity Squamous Cell Carcinoma","Recurrent Pharyngeal Squamous Cell Carcinoma","Resectable Head and Neck Squamous Cell Carcinoma",[81],{"trials":1239,"activeCount":117},[1240],{"nctId":1241,"briefTitle":1242,"status":99,"phases":1243,"primaryCompletion":1244,"completion":1244,"start":1245,"enrollment":92,"conditions":1246,"interventions":1252},"NCT04120454","Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer",[85],"2023-08-19","2020-06-17",[1247,1248,1249,1250,1251],"Metastatic Lung Non-Small Cell Carcinoma","Recurrent Lung Non-Small Cell Carcinoma","Stage IV Lung Cancer AJCC v8","Stage IVA Lung Cancer AJCC v8","Stage IVB Lung Cancer AJCC v8",[81,1253],"Ramucirumab",{"trials":1255,"activeCount":117},[],{"trials":1257,"activeCount":117},[],{"trials":1259,"activeCount":117},[],{"intervention":332,"totalTrials":134,"cells":1261},{"EARLY_PHASE1":1262,"PHASE1":1264,"PHASE2":1270,"PHASE3":1272,"PHASE4":1274,"NA":1276},{"trials":1263,"activeCount":117},[],{"trials":1265,"activeCount":134,"soonestReadout":65},[1266],{"nctId":63,"briefTitle":64,"status":125,"phases":1267,"primaryCompletion":65,"completion":65,"start":319,"enrollment":320,"conditions":1268,"interventions":1269},[84],[322,323,324,325,326,327,328,329,330],[66,332,257,333,334],{"trials":1271,"activeCount":117},[],{"trials":1273,"activeCount":117},[],{"trials":1275,"activeCount":117},[],{"trials":1277,"activeCount":117},[],{"intervention":333,"totalTrials":134,"cells":1279},{"EARLY_PHASE1":1280,"PHASE1":1282,"PHASE2":1288,"PHASE3":1290,"PHASE4":1292,"NA":1294},{"trials":1281,"activeCount":117},[],{"trials":1283,"activeCount":134,"soonestReadout":65},[1284],{"nctId":63,"briefTitle":64,"status":125,"phases":1285,"primaryCompletion":65,"completion":65,"start":319,"enrollment":320,"conditions":1286,"interventions":1287},[84],[322,323,324,325,326,327,328,329,330],[66,332,257,333,334],{"trials":1289,"activeCount":117},[],{"trials":1291,"activeCount":117},[],{"trials":1293,"activeCount":117},[],{"trials":1295,"activeCount":117},[],{"intervention":52,"totalTrials":134,"cells":1297},{"EARLY_PHASE1":1298,"PHASE1":1300,"PHASE2":1308,"PHASE3":1310,"PHASE4":1312,"NA":1314},{"trials":1299,"activeCount":117},[],{"trials":1301,"activeCount":134,"soonestReadout":51},[1302],{"nctId":49,"briefTitle":50,"status":660,"phases":1303,"primaryCompletion":51,"completion":144,"start":1304,"enrollment":695,"conditions":1305,"interventions":1307},[84],"2019-02-07",[1306],"Lung Non-Small Cell Carcinoma",[52],{"trials":1309,"activeCount":117},[],{"trials":1311,"activeCount":117},[],{"trials":1313,"activeCount":117},[],{"trials":1315,"activeCount":117},[],{"intervention":1317,"totalTrials":134,"cells":1318},"Anti-GARP Chimeric Antigen Receptor-T Cells",{"EARLY_PHASE1":1319,"PHASE1":1321,"PHASE2":1337,"PHASE3":1339,"PHASE4":1341,"NA":1343},{"trials":1320,"activeCount":117},[],{"trials":1322,"activeCount":134,"soonestReadout":1327},[1323],{"nctId":1324,"briefTitle":1325,"status":125,"phases":1326,"primaryCompletion":1327,"completion":1327,"start":1328,"enrollment":164,"conditions":1329,"interventions":1336},"NCT06964737","Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas",[84],"2027-05-31","2025-05-21",[1330,1331,1332,1333,1334,1335],"Recurrent Malignant Glioma","Recurrent WHO Grade 3 Glioma","Recurrent WHO Grade 4 Glioma","WHO Grade 2 Glioma","WHO Grade 3 Glioma","WHO Grade 4 Glioma",[1317],{"trials":1338,"activeCount":117},[],{"trials":1340,"activeCount":117},[],{"trials":1342,"activeCount":117},[],{"trials":1344,"activeCount":117},[],{"intervention":77,"totalTrials":134,"cells":1346},{"EARLY_PHASE1":1347,"PHASE1":1349,"PHASE2":1355,"PHASE3":1357,"PHASE4":1359,"NA":1361},{"trials":1348,"activeCount":117},[],{"trials":1350,"activeCount":134,"soonestReadout":65},[1351],{"nctId":75,"briefTitle":76,"status":125,"phases":1352,"primaryCompletion":65,"completion":65,"start":1061,"enrollment":1062,"conditions":1353,"interventions":1354},[84],[1064,1065,1066,1067,1068,1069,703,1070,1071,1072,1073,1074,1075,707,1076],[77,1052,1078],{"trials":1356,"activeCount":117},[],{"trials":1358,"activeCount":117},[],{"trials":1360,"activeCount":117},[],{"trials":1362,"activeCount":117},[],{"intervention":42,"totalTrials":134,"cells":1364},{"EARLY_PHASE1":1365,"PHASE1":1367,"PHASE2":1376,"PHASE3":1378,"PHASE4":1380,"NA":1382},{"trials":1366,"activeCount":117},[],{"trials":1368,"activeCount":134,"soonestReadout":41},[1369],{"nctId":39,"briefTitle":40,"status":125,"phases":1370,"primaryCompletion":41,"completion":1371,"start":1372,"enrollment":1062,"conditions":1373,"interventions":1374},[84],"2029-07-31","2022-01-18",[1247,1249,1250,1251],[42,1375],"Tegavivint",{"trials":1377,"activeCount":117},[],{"trials":1379,"activeCount":117},[],{"trials":1381,"activeCount":117},[],{"trials":1383,"activeCount":117},[],{"intervention":1375,"totalTrials":134,"cells":1385},{"EARLY_PHASE1":1386,"PHASE1":1388,"PHASE2":1394,"PHASE3":1396,"PHASE4":1398,"NA":1400},{"trials":1387,"activeCount":117},[],{"trials":1389,"activeCount":134,"soonestReadout":41},[1390],{"nctId":39,"briefTitle":40,"status":125,"phases":1391,"primaryCompletion":41,"completion":1371,"start":1372,"enrollment":1062,"conditions":1392,"interventions":1393},[84],[1247,1249,1250,1251],[42,1375],{"trials":1395,"activeCount":117},[],{"trials":1397,"activeCount":117},[],{"trials":1399,"activeCount":117},[],{"trials":1401,"activeCount":117},[],{"intervention":1403,"totalTrials":134,"cells":1404},"Nicotine",{"EARLY_PHASE1":1405,"PHASE1":1407,"PHASE2":1419,"PHASE3":1421,"PHASE4":1423,"NA":1425},{"trials":1406,"activeCount":117},[],{"trials":1408,"activeCount":134,"soonestReadout":65},[1409],{"nctId":1410,"briefTitle":1411,"status":142,"phases":1412,"primaryCompletion":65,"completion":65,"start":1413,"enrollment":889,"conditions":1414,"interventions":1416},"NCT07585006","Comparative Evaluation of Nicotine Analogs",[84],"2026-06-01",[27,1415],"Addiction",[1403,1417,1418],"6-Methyl Nicotine","nicotinamide",{"trials":1420,"activeCount":117},[],{"trials":1422,"activeCount":117},[],{"trials":1424,"activeCount":117},[],{"trials":1426,"activeCount":117},[],{"intervention":1417,"totalTrials":134,"cells":1428},{"EARLY_PHASE1":1429,"PHASE1":1431,"PHASE2":1437,"PHASE3":1439,"PHASE4":1441,"NA":1443},{"trials":1430,"activeCount":117},[],{"trials":1432,"activeCount":134,"soonestReadout":65},[1433],{"nctId":1410,"briefTitle":1411,"status":142,"phases":1434,"primaryCompletion":65,"completion":65,"start":1413,"enrollment":889,"conditions":1435,"interventions":1436},[84],[27,1415],[1403,1417,1418],{"trials":1438,"activeCount":117},[],{"trials":1440,"activeCount":117},[],{"trials":1442,"activeCount":117},[],{"trials":1444,"activeCount":117},[],{"intervention":1418,"totalTrials":134,"cells":1446},{"EARLY_PHASE1":1447,"PHASE1":1449,"PHASE2":1455,"PHASE3":1457,"PHASE4":1459,"NA":1461},{"trials":1448,"activeCount":117},[],{"trials":1450,"activeCount":134,"soonestReadout":65},[1451],{"nctId":1410,"briefTitle":1411,"status":142,"phases":1452,"primaryCompletion":65,"completion":65,"start":1413,"enrollment":889,"conditions":1453,"interventions":1454},[84],[27,1415],[1403,1417,1418],{"trials":1456,"activeCount":117},[],{"trials":1458,"activeCount":117},[],{"trials":1460,"activeCount":117},[],{"trials":1462,"activeCount":117},[],{"intervention":303,"totalTrials":134,"cells":1464},{"EARLY_PHASE1":1465,"PHASE1":1471,"PHASE2":1473,"PHASE3":1475,"PHASE4":1477,"NA":1479},{"trials":1466,"activeCount":134,"soonestReadout":65},[1467],{"nctId":262,"briefTitle":263,"status":125,"phases":1468,"primaryCompletion":65,"completion":65,"start":265,"enrollment":266,"conditions":1469,"interventions":1470},[83],[268,269,270,271,272,273,274,275,276,277,278,279,280,281,282,283,284,285,286,287,288,289,290,291,292,293,294,295,296,297,298,299,300],[66,302,303,257],{"trials":1472,"activeCount":117},[],{"trials":1474,"activeCount":117},[],{"trials":1476,"activeCount":117},[],{"trials":1478,"activeCount":117},[],{"trials":1480,"activeCount":117},[],{"intervention":802,"totalTrials":1482,"cells":1483},4,{"EARLY_PHASE1":1484,"PHASE1":1490,"PHASE2":1492,"PHASE3":1494,"PHASE4":1496,"NA":1498},{"trials":1485,"activeCount":117},[1486],{"nctId":791,"briefTitle":792,"status":99,"phases":1487,"primaryCompletion":794,"completion":795,"start":796,"enrollment":797,"conditions":1488,"interventions":1489},[83],[799,800],[133,802],{"trials":1491,"activeCount":117},[],{"trials":1493,"activeCount":117},[],{"trials":1495,"activeCount":117},[],{"trials":1497,"activeCount":117},[],{"trials":1499,"activeCount":134,"soonestReadout":1504},[1500,1509,1517],{"nctId":1501,"briefTitle":1502,"status":125,"phases":1503,"primaryCompletion":1504,"completion":1504,"start":1505,"enrollment":1506,"conditions":1507,"interventions":1508},"NCT06260683","A Comprehensive Evaluation of Tobacco-Flavored vs. Non-Tobacco Flavored E-cigarettes on Smoking Behavior",[88],"2028-04-12","2024-04-10",1500,[35],[802],{"nctId":1510,"briefTitle":1511,"status":99,"phases":1512,"primaryCompletion":1513,"completion":1513,"start":1514,"enrollment":589,"conditions":1515,"interventions":1516},"NCT06745154","Evaluating the Impact of Quitting Using Executive Function Strategy Training (QUEST) on Smoking Cessation in Homeless Young Adult Smokers",[88],"2023-08-30","2023-06-26",[35],[802],{"nctId":1518,"briefTitle":1519,"status":1108,"phases":1520,"primaryCompletion":1521,"completion":1521,"start":1522,"enrollment":117,"conditions":1523,"interventions":1534},"NCT05412875","Pilot Trial of E Cigarettes in Pts Diagnosed With Cancer of the Head, Neck, and Lung",[88],"2024-01-31","2024-01-01",[1524,1306,1525,1526,1527,1528,1529,1530,1531,323,324,325,1532,326,327,328,329,1533],"Head and Neck Squamous Cell Carcinoma","Stage I Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8","Stage I Lung Cancer AJCC v8","Stage IA1 Lung Cancer AJCC v8","Stage IA2 Lung Cancer AJCC v8","Stage IA3 Lung Cancer AJCC v8","Stage IB Lung Cancer AJCC v8","Stage II Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8","Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8","Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8",[802],{"intervention":1536,"totalTrials":134,"cells":1537},"Loperamide Hydrochloride",{"EARLY_PHASE1":1538,"PHASE1":1540,"PHASE2":1542,"PHASE3":1544,"PHASE4":1546,"NA":1548},{"trials":1539,"activeCount":117},[],{"trials":1541,"activeCount":117},[],{"trials":1543,"activeCount":117},[],{"trials":1545,"activeCount":117},[],{"trials":1547,"activeCount":117},[],{"trials":1549,"activeCount":134,"soonestReadout":1554},[1550],{"nctId":1551,"briefTitle":1552,"status":125,"phases":1553,"primaryCompletion":1554,"completion":1554,"start":46,"enrollment":1555,"conditions":1556,"interventions":1558},"NCT06424522","A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal Cancer Patients",[88],"2028-12-31",80,[1557,1041],"Low Anterior Resection Syndrome",[1536],{"intervention":1560,"totalTrials":134,"cells":1561},"Standardized E-Cigarette Nicotine Administration",{"EARLY_PHASE1":1562,"PHASE1":1564,"PHASE2":1566,"PHASE3":1568,"PHASE4":1570,"NA":1572},{"trials":1563,"activeCount":117},[],{"trials":1565,"activeCount":117},[],{"trials":1567,"activeCount":117},[],{"trials":1569,"activeCount":117},[],{"trials":1571,"activeCount":117},[],{"trials":1573,"activeCount":134,"soonestReadout":144},[1574],{"nctId":1575,"briefTitle":1576,"status":142,"phases":1577,"primaryCompletion":144,"completion":144,"start":1578,"enrollment":1036,"conditions":1579,"interventions":1580},"NCT07604246","Evaluating the Effect of Nicotine on Eye Movements and Related Behaviors in Electronic Cigarette Users, NICS-EYES Trial",[88],"2026-08-01",[35],[1560],{"intervention":167,"totalTrials":134,"cells":1582},{"EARLY_PHASE1":1583,"PHASE1":1585,"PHASE2":1587,"PHASE3":1589,"PHASE4":1591,"NA":1593},{"trials":1584,"activeCount":117},[],{"trials":1586,"activeCount":117},[],{"trials":1588,"activeCount":117},[],{"trials":1590,"activeCount":117},[],{"trials":1592,"activeCount":117},[],{"trials":1594,"activeCount":134,"soonestReadout":65},[1595],{"nctId":160,"briefTitle":161,"status":125,"phases":1596,"primaryCompletion":65,"completion":65,"start":163,"enrollment":164,"conditions":1597,"interventions":1598},[88],[35],[91,167],{"intervention":443,"totalTrials":134,"cells":1600},{"EARLY_PHASE1":1601,"PHASE1":1603,"PHASE2":1605,"PHASE3":1607,"PHASE4":1613,"NA":1615},{"trials":1602,"activeCount":117},[],{"trials":1604,"activeCount":117},[],{"trials":1606,"activeCount":117},[],{"trials":1608,"activeCount":117},[1609],{"nctId":431,"briefTitle":432,"status":99,"phases":1610,"primaryCompletion":434,"completion":434,"start":435,"enrollment":436,"conditions":1611,"interventions":1612},[85,86],[438,29,353,354,18,355,356,21,357,358,359,439,32,440,360,361,362,363,364,365,366,367,368,369,441],[443,444,445,446,257,447],{"trials":1614,"activeCount":117},[],{"trials":1616,"activeCount":117},[],{"intervention":445,"totalTrials":134,"cells":1618},{"EARLY_PHASE1":1619,"PHASE1":1621,"PHASE2":1623,"PHASE3":1625,"PHASE4":1631,"NA":1633},{"trials":1620,"activeCount":117},[],{"trials":1622,"activeCount":117},[],{"trials":1624,"activeCount":117},[],{"trials":1626,"activeCount":117},[1627],{"nctId":431,"briefTitle":432,"status":99,"phases":1628,"primaryCompletion":434,"completion":434,"start":435,"enrollment":436,"conditions":1629,"interventions":1630},[85,86],[438,29,353,354,18,355,356,21,357,358,359,439,32,440,360,361,362,363,364,365,366,367,368,369,441],[443,444,445,446,257,447],{"trials":1632,"activeCount":117},[],{"trials":1634,"activeCount":117},[],{"intervention":446,"totalTrials":134,"cells":1636},{"EARLY_PHASE1":1637,"PHASE1":1639,"PHASE2":1641,"PHASE3":1643,"PHASE4":1649,"NA":1651},{"trials":1638,"activeCount":117},[],{"trials":1640,"activeCount":117},[],{"trials":1642,"activeCount":117},[],{"trials":1644,"activeCount":117},[1645],{"nctId":431,"briefTitle":432,"status":99,"phases":1646,"primaryCompletion":434,"completion":434,"start":435,"enrollment":436,"conditions":1647,"interventions":1648},[85,86],[438,29,353,354,18,355,356,21,357,358,359,439,32,440,360,361,362,363,364,365,366,367,368,369,441],[443,444,445,446,257,447],{"trials":1650,"activeCount":117},[],{"trials":1652,"activeCount":117},[],{"intervention":447,"totalTrials":134,"cells":1654},{"EARLY_PHASE1":1655,"PHASE1":1657,"PHASE2":1659,"PHASE3":1661,"PHASE4":1667,"NA":1669},{"trials":1656,"activeCount":117},[],{"trials":1658,"activeCount":117},[],{"trials":1660,"activeCount":117},[],{"trials":1662,"activeCount":117},[1663],{"nctId":431,"briefTitle":432,"status":99,"phases":1664,"primaryCompletion":434,"completion":434,"start":435,"enrollment":436,"conditions":1665,"interventions":1666},[85,86],[438,29,353,354,18,355,356,21,357,358,359,439,32,440,360,361,362,363,364,365,366,367,368,369,441],[443,444,445,446,257,447],{"trials":1668,"activeCount":117},[],{"trials":1670,"activeCount":117},[],{"intervention":1129,"totalTrials":92,"cells":1672},{"EARLY_PHASE1":1673,"PHASE1":1675,"PHASE2":1677,"PHASE3":1728,"PHASE4":1730,"NA":1732},{"trials":1674,"activeCount":117},[],{"trials":1676,"activeCount":117},[],{"trials":1678,"activeCount":117},[1679,1683,1695,1699,1703,1719],{"nctId":1177,"briefTitle":1178,"status":99,"phases":1680,"primaryCompletion":1180,"completion":1181,"start":1182,"enrollment":525,"conditions":1681,"interventions":1682},[85],[1184,1185],[1078,1129,1187],{"nctId":1684,"briefTitle":1685,"status":99,"phases":1686,"primaryCompletion":1687,"completion":1688,"start":1689,"enrollment":1036,"conditions":1690,"interventions":1693},"NCT00201877","Velcade (Bortezomib, PS-341) and Rituximab in Relapsed\u002FRefractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma",[85],"2009-06","2012-03","2004-12",[1691,1692],"Non-Hodgkin's Lymphoma","Mantle Cell Lymphoma",[1694,1129],"Velcade",{"nctId":1106,"briefTitle":1107,"status":1108,"phases":1696,"primaryCompletion":1110,"completion":1110,"start":1111,"enrollment":117,"conditions":1697,"interventions":1698},[85],[1113],[1115,1116,1117,1091,1094,629,1103,1104],{"nctId":1119,"briefTitle":1120,"status":99,"phases":1700,"primaryCompletion":1122,"completion":1123,"start":1124,"enrollment":320,"conditions":1701,"interventions":1702},[85],[1126],[1128,1129,1052],{"nctId":1704,"briefTitle":1705,"status":387,"phases":1706,"primaryCompletion":1707,"completion":539,"start":1708,"enrollment":25,"conditions":1709,"interventions":1717},"NCT01812005","Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",[85],"2015-10-14","2013-05-21",[1710,1711,1712,1713,699,700,701,1714,702,1715,1716],"Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue","Nodal Marginal Zone B-cell Lymphoma","Recurrent Adult Burkitt Lymphoma","Recurrent Adult Diffuse Large Cell Lymphoma","Recurrent Mantle Cell Lymphoma","Splenic Marginal Zone Lymphoma","Waldenström Macroglobulinemia",[1718,1116],"alisertib",{"nctId":1720,"briefTitle":1721,"status":99,"phases":1722,"primaryCompletion":1723,"completion":1723,"start":1724,"enrollment":717,"conditions":1725,"interventions":1727},"NCT01206777","Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies",[85],"2013-04","2010-10",[1726],"Indolent or Intermediate Grade B-cell Malignancy",[1129],{"trials":1729,"activeCount":117},[],{"trials":1731,"activeCount":117},[],{"trials":1733,"activeCount":117},[],{"intervention":1139,"totalTrials":1053,"cells":1735},{"EARLY_PHASE1":1736,"PHASE1":1738,"PHASE2":1789,"PHASE3":1809,"PHASE4":1811,"NA":1813},{"trials":1737,"activeCount":117},[],{"trials":1739,"activeCount":117},[1740,1750,1754],{"nctId":1741,"briefTitle":1742,"status":99,"phases":1743,"primaryCompletion":1744,"completion":1745,"start":1746,"enrollment":589,"conditions":1747,"interventions":1748},"NCT00201812","Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors",[84],"2004-01","2005-05","2000-11",[413],[1749,1139,444],"Etanercept",{"nctId":536,"briefTitle":537,"status":99,"phases":1751,"primaryCompletion":539,"completion":539,"start":540,"enrollment":541,"conditions":1752,"interventions":1753},[84],[543,544,545,546,547,548,549,550,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,576,577,578,579],[581,380,582],{"nctId":1755,"briefTitle":1756,"status":1108,"phases":1757,"primaryCompletion":1758,"completion":1758,"start":1758,"enrollment":117,"conditions":1759,"interventions":1785},"NCT05296005","Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers",[84],"2025-12-31",[1760,1761,1762,1763,1764,1765,1766,1767,1768,1769,1770,1771,1772,1773,1774,1775,1776,1777,1778,1779,1780,1781,1782,1783,1784],"Clinical Stage I Gastric Cancer AJCC v8","Clinical Stage II Gastric Cancer AJCC v8","Clinical Stage IIA Gastric Cancer AJCC v8","Clinical Stage IIB Gastric Cancer AJCC v8","Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8","Clinical Stage III Gastric Cancer AJCC v8","Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8","Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8","Gastric Adenocarcinoma","Pathologic Stage IB Gastric Cancer AJCC v8","Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage II Gastric Cancer AJCC v8","Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage IIA Gastric Cancer AJCC v8","Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage IIB Gastric Cancer AJCC v8","Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage III Gastric Cancer AJCC v8","Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage IIIA Gastric Cancer AJCC v8","Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage IIIB Gastric Cancer AJCC v8","Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage IIIC Gastric Cancer AJCC v8","Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8",[417,1139,1786,1787,1788],"Fluorouracil","Leucovorin","Oxaliplatin",{"trials":1790,"activeCount":117},[1791,1805],{"nctId":1792,"briefTitle":1793,"status":99,"phases":1794,"primaryCompletion":1795,"start":1796,"enrollment":92,"conditions":1797,"interventions":1803},"NCT01129206","Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy",[85],"2012-09","2010-07",[1798,1799,1800,1801,1802],"Adenocarcinoma of the Esophagus","Adenocarcinomas of the Gastroesophageal Junction","Recurrent Esophageal Cancer","Squamous Cell Carcinoma of the Esophagus","Stage IV Esophageal Cancer",[1804,582],"pralatrexate",{"nctId":1131,"briefTitle":1132,"status":99,"phases":1806,"primaryCompletion":1134,"completion":1135,"start":489,"enrollment":1136,"conditions":1807,"interventions":1808},[85],[15],[1139,1140,1052],{"trials":1810,"activeCount":117},[],{"trials":1812,"activeCount":117},[],{"trials":1814,"activeCount":117},[],{"intervention":1816,"totalTrials":1482,"cells":1817},"lenalidomide",{"EARLY_PHASE1":1818,"PHASE1":1820,"PHASE2":1842,"PHASE3":1880,"PHASE4":1882,"NA":1884},{"trials":1819,"activeCount":117},[],{"trials":1821,"activeCount":117},[1822,1832],{"nctId":1823,"briefTitle":1824,"status":387,"phases":1825,"primaryCompletion":1826,"completion":1826,"start":1827,"enrollment":155,"conditions":1828,"interventions":1830},"NCT02077959","Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma",[84],"2019-05-24","2014-03-03",[1829],"Multiple Myeloma",[1816,1831],"pidilizumab",{"nctId":1833,"briefTitle":1834,"status":99,"phases":1835,"primaryCompletion":1836,"completion":1837,"start":1838,"enrollment":695,"conditions":1839,"interventions":1841},"NCT00729118","Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma",[84],"2019-12-26","2020-05-04","2008-09-26",[1829,1840],"Plasma Cell Neoplasm",[1816,594],{"trials":1843,"activeCount":117},[1844,1865],{"nctId":1845,"briefTitle":1846,"status":99,"phases":1847,"primaryCompletion":1848,"completion":1848,"start":1849,"enrollment":1850,"conditions":1851,"interventions":1863},"NCT02005289","Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL",[85],"2025-05-20","2014-01-17",41,[1852,1853,1854,1855,1072,1856,1857,1858,1859,1860,1861,1862],"Contiguous Stage II Small Lymphocytic Lymphoma","Noncontiguous Stage II Small Lymphocytic Lymphoma","Prolymphocytic Leukemia","Recurrent Small Lymphocytic Lymphoma","Stage I Chronic Lymphocytic Leukemia","Stage I Small Lymphocytic Lymphoma","Stage II Chronic Lymphocytic Leukemia","Stage III Chronic Lymphocytic Leukemia","Stage III Small Lymphocytic Lymphoma","Stage IV Chronic Lymphocytic Leukemia","Stage IV Small Lymphocytic Lymphoma",[1864,1816],"MOR00208",{"nctId":1866,"briefTitle":1867,"status":99,"phases":1868,"primaryCompletion":1869,"completion":1869,"start":1870,"enrollment":1062,"conditions":1871,"interventions":1878},"NCT01460940","A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma",[85],"2016-11-16","2011-10-13",[1872,1873,1874,1875,1876,1877],"Adult Lymphocyte Depletion Hodgkin Lymphoma","Adult Lymphocyte Predominant Hodgkin Lymphoma","Adult Mixed Cellularity Hodgkin Lymphoma","Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma","Adult Nodular Sclerosis Hodgkin Lymphoma","Recurrent Adult Hodgkin Lymphoma",[1879,1816],"panobinostat",{"trials":1881,"activeCount":117},[],{"trials":1883,"activeCount":117},[],{"trials":1885,"activeCount":117},[],{"intervention":629,"totalTrials":1482,"cells":1887},{"EARLY_PHASE1":1888,"PHASE1":1890,"PHASE2":1902,"PHASE3":1916,"PHASE4":1918,"NA":1920},{"trials":1889,"activeCount":117},[],{"trials":1891,"activeCount":117},[1892],{"nctId":1893,"briefTitle":1894,"status":387,"phases":1895,"primaryCompletion":1896,"completion":487,"start":1897,"enrollment":164,"conditions":1898,"interventions":1899},"NCT00124644","Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia",[84],"2007-12","2006-03",[1089],[1092,1900,629,1901],"daunorubicin hydrochloride","tipifarnib",{"trials":1903,"activeCount":117},[1904,1908,1912],{"nctId":690,"briefTitle":691,"status":99,"phases":1905,"primaryCompletion":693,"completion":693,"start":694,"enrollment":695,"conditions":1906,"interventions":1907},[84,85],[697,698,699,700,701,702,703,704,705,706,707,708],[710,711,712,713,674],{"nctId":1106,"briefTitle":1107,"status":1108,"phases":1909,"primaryCompletion":1110,"completion":1110,"start":1111,"enrollment":117,"conditions":1910,"interventions":1911},[85],[1113],[1115,1116,1117,1091,1094,629,1103,1104],{"nctId":616,"briefTitle":617,"status":99,"phases":1913,"primaryCompletion":619,"completion":619,"start":620,"enrollment":621,"conditions":1914,"interventions":1915},[85],[623,624,625,626,627],[380,629],{"trials":1917,"activeCount":117},[],{"trials":1919,"activeCount":117},[],{"trials":1921,"activeCount":117},[],{"intervention":315,"totalTrials":541,"cells":1923},{"EARLY_PHASE1":1924,"PHASE1":1926,"PHASE2":1936,"PHASE3":1945,"PHASE4":1947,"NA":1949},{"trials":1925,"activeCount":117},[],{"trials":1927,"activeCount":117},[1928,1932],{"nctId":307,"briefTitle":308,"status":309,"phases":1929,"start":311,"conditions":1930,"interventions":1931},[84],[313],[315,316],{"nctId":1755,"briefTitle":1756,"status":1108,"phases":1933,"primaryCompletion":1758,"completion":1758,"start":1758,"enrollment":117,"conditions":1934,"interventions":1935},[84],[1760,1761,1762,1763,1764,1765,1766,1767,1768,1769,1770,1771,1772,1773,1774,1775,1776,1777,1778,1779,1780,1781,1782,1783,1784],[417,1139,1786,1787,1788],{"trials":1937,"activeCount":117},[1938],{"nctId":1939,"briefTitle":1940,"status":99,"phases":1941,"completion":599,"start":1942,"conditions":1943,"interventions":1944},"NCT00005035","Oxaliplatin in Treating Patients With Advanced Head and Neck Cancer",[85],"1999-12",[392],[315],{"trials":1946,"activeCount":117},[],{"trials":1948,"activeCount":117},[],{"trials":1950,"activeCount":117},[],{"intervention":1092,"totalTrials":541,"cells":1952},{"EARLY_PHASE1":1953,"PHASE1":1955,"PHASE2":1961,"PHASE3":1971,"PHASE4":1973,"NA":1975},{"trials":1954,"activeCount":117},[],{"trials":1956,"activeCount":117},[1957],{"nctId":1893,"briefTitle":1894,"status":387,"phases":1958,"primaryCompletion":1896,"completion":487,"start":1897,"enrollment":164,"conditions":1959,"interventions":1960},[84],[1089],[1092,1900,629,1901],{"trials":1962,"activeCount":117},[1963,1967],{"nctId":690,"briefTitle":691,"status":99,"phases":1964,"primaryCompletion":693,"completion":693,"start":694,"enrollment":695,"conditions":1965,"interventions":1966},[84,85],[697,698,699,700,701,702,703,704,705,706,707,708],[710,711,712,713,674],{"nctId":1082,"briefTitle":1083,"status":309,"phases":1968,"primaryCompletion":1085,"start":1086,"enrollment":1087,"conditions":1969,"interventions":1970},[85],[1089],[1091,1092,1093,1094,1095,1096,1097,1098,1099,1100,1101,1102,1103,1104],{"trials":1972,"activeCount":117},[],{"trials":1974,"activeCount":117},[],{"trials":1976,"activeCount":117},[],{"intervention":495,"totalTrials":541,"cells":1978},{"EARLY_PHASE1":1979,"PHASE1":1981,"PHASE2":1994,"PHASE3":2011,"PHASE4":2013,"NA":2015},{"trials":1980,"activeCount":117},[],{"trials":1982,"activeCount":117},[1983],{"nctId":1984,"briefTitle":1985,"status":99,"phases":1986,"primaryCompletion":1987,"completion":1988,"start":1989,"enrollment":1990,"conditions":1991,"interventions":1993},"NCT00841555","Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Astrocytoma",[84],"2013-02-13","2014-11-25","2009-02-13",9,[1992],"Glioblastoma Multiforme\u002FAnaplastic Astrocytoma",[495],{"trials":1995,"activeCount":117},[1996,2000],{"nctId":484,"briefTitle":485,"status":99,"phases":1997,"primaryCompletion":487,"completion":488,"start":489,"enrollment":490,"conditions":1998,"interventions":1999},[84,85],[492,493],[480,495],{"nctId":2001,"briefTitle":2002,"status":99,"phases":2003,"primaryCompletion":2004,"completion":2005,"start":1745,"enrollment":134,"conditions":2006,"interventions":2009},"NCT00362570","Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma",[85],"2007-04","2011-03",[2007,2008],"Oligoastrocytoma, Mixed","Anaplastic Oligodendroglioma",[2010],"Temozolomide",{"trials":2012,"activeCount":117},[],{"trials":2014,"activeCount":117},[],{"trials":2016,"activeCount":117},[],{"intervention":1187,"totalTrials":9,"cells":2018},{"EARLY_PHASE1":2019,"PHASE1":2021,"PHASE2":2032,"PHASE3":2038,"PHASE4":2040,"NA":2042},{"trials":2020,"activeCount":117},[],{"trials":2022,"activeCount":117},[2023],{"nctId":2024,"briefTitle":2025,"status":99,"phases":2026,"primaryCompletion":2027,"completion":2028,"start":599,"enrollment":1062,"conditions":2029,"interventions":2030},"NCT00323323","CHOP and Campath-1H in Previously Untreated Aggressive T\u002FNK-Cell Lymphomas",[84],"2012-08","2016-10",[1691],[2031,1187],"CHOP",{"trials":2033,"activeCount":117},[2034],{"nctId":1177,"briefTitle":1178,"status":99,"phases":2035,"primaryCompletion":1180,"completion":1181,"start":1182,"enrollment":525,"conditions":2036,"interventions":2037},[85],[1184,1185],[1078,1129,1187],{"trials":2039,"activeCount":117},[],{"trials":2041,"activeCount":117},[],{"trials":2043,"activeCount":117},[],{"intervention":1694,"totalTrials":9,"cells":2045},{"EARLY_PHASE1":2046,"PHASE1":2048,"PHASE2":2062,"PHASE3":2068,"PHASE4":2070,"NA":2072},{"trials":2047,"activeCount":117},[],{"trials":2049,"activeCount":117},[2050],{"nctId":2051,"briefTitle":2052,"status":99,"phases":2053,"primaryCompletion":2054,"completion":2055,"start":2056,"enrollment":16,"conditions":2057,"interventions":2060},"NCT00624936","Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes",[84],"2009-12","2014-06","2008-04",[1089,2058,2059],"Myelodysplastic Syndromes","Myelodysplastic\u002FMyeloproliferative Neoplasms",[2061,1694],"Vidaza",{"trials":2063,"activeCount":117},[2064],{"nctId":1684,"briefTitle":1685,"status":99,"phases":2065,"primaryCompletion":1687,"completion":1688,"start":1689,"enrollment":1036,"conditions":2066,"interventions":2067},[85],[1691,1692],[1694,1129],{"trials":2069,"activeCount":117},[],{"trials":2071,"activeCount":117},[],{"trials":2073,"activeCount":117},[],{"intervention":1128,"totalTrials":9,"cells":2075},{"EARLY_PHASE1":2076,"PHASE1":2078,"PHASE2":2080,"PHASE3":2096,"PHASE4":2098,"NA":2100},{"trials":2077,"activeCount":117},[],{"trials":2079,"activeCount":117},[],{"trials":2081,"activeCount":117},[2082,2092],{"nctId":2083,"briefTitle":2084,"status":99,"phases":2085,"primaryCompletion":2086,"completion":2087,"start":2088,"enrollment":525,"conditions":2089,"interventions":2091},"NCT00201786","Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease",[85],"2007-10","2013-07","2003-07",[2090],"Graft-Versus-Host Disease",[1128],{"nctId":1119,"briefTitle":1120,"status":99,"phases":2093,"primaryCompletion":1122,"completion":1123,"start":1124,"enrollment":320,"conditions":2094,"interventions":2095},[85],[1126],[1128,1129,1052],{"trials":2097,"activeCount":117},[],{"trials":2099,"activeCount":117},[],{"trials":2101,"activeCount":117},[],{"intervention":479,"totalTrials":9,"cells":2103},{"EARLY_PHASE1":2104,"PHASE1":2106,"PHASE2":2108,"PHASE3":2118,"PHASE4":2120,"NA":2122},{"trials":2105,"activeCount":117},[],{"trials":2107,"activeCount":117},[],{"trials":2109,"activeCount":117},[2110,2114],{"nctId":470,"briefTitle":471,"status":99,"phases":2111,"primaryCompletion":473,"completion":474,"start":475,"enrollment":476,"conditions":2112,"interventions":2113},[85],[15],[479,480,481,482],{"nctId":505,"briefTitle":506,"status":99,"phases":2115,"primaryCompletion":508,"completion":509,"start":510,"enrollment":266,"conditions":2116,"interventions":2117},[85],[512,513,514],[516,517,66],{"trials":2119,"activeCount":117},[],{"trials":2121,"activeCount":117},[],{"trials":2123,"activeCount":117},[],{"intervention":481,"totalTrials":9,"cells":2125},{"EARLY_PHASE1":2126,"PHASE1":2128,"PHASE2":2130,"PHASE3":2145,"PHASE4":2147,"NA":2149},{"trials":2127,"activeCount":117},[],{"trials":2129,"activeCount":117},[],{"trials":2131,"activeCount":117},[2132,2136],{"nctId":470,"briefTitle":471,"status":99,"phases":2133,"primaryCompletion":473,"completion":474,"start":475,"enrollment":476,"conditions":2134,"interventions":2135},[85],[15],[479,480,481,482],{"nctId":2137,"briefTitle":2138,"status":99,"phases":2139,"primaryCompletion":2140,"completion":1723,"start":2141,"enrollment":1482,"conditions":2142,"interventions":2144},"NCT00738361","Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery",[85],"2012-07","2008-08",[2143],"Intraocular Melanoma",[481],{"trials":2146,"activeCount":117},[],{"trials":2148,"activeCount":117},[],{"trials":2150,"activeCount":117},[],{"intervention":2152,"totalTrials":9,"cells":2153},"Exemestane",{"EARLY_PHASE1":2154,"PHASE1":2156,"PHASE2":2158,"PHASE3":2178,"PHASE4":2180,"NA":2182},{"trials":2155,"activeCount":117},[],{"trials":2157,"activeCount":117},[],{"trials":2159,"activeCount":117},[2160,2169],{"nctId":2161,"briefTitle":2162,"status":99,"phases":2163,"primaryCompletion":408,"completion":2164,"start":2088,"enrollment":2165,"conditions":2166,"interventions":2167},"NCT00201773","Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer",[85],"2011-06",22,[15],[2152,2168],"Celecoxib",{"nctId":2170,"briefTitle":2171,"status":99,"phases":2172,"primaryCompletion":2173,"completion":1135,"start":2174,"enrollment":250,"conditions":2175,"interventions":2176},"NCT00201864","Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer",[85],"2012-06","2005-09",[15],[2152,2177],"Fulvestrant",{"trials":2179,"activeCount":117},[],{"trials":2181,"activeCount":117},[],{"trials":2183,"activeCount":117},[],{"intervention":2168,"totalTrials":9,"cells":2185},{"EARLY_PHASE1":2186,"PHASE1":2188,"PHASE2":2190,"PHASE3":2205,"PHASE4":2207,"NA":2209},{"trials":2187,"activeCount":117},[],{"trials":2189,"activeCount":117},[],{"trials":2191,"activeCount":117},[2192,2196],{"nctId":2161,"briefTitle":2162,"status":99,"phases":2193,"primaryCompletion":408,"completion":2164,"start":2088,"enrollment":2165,"conditions":2194,"interventions":2195},[85],[15],[2152,2168],{"nctId":2197,"briefTitle":2198,"status":99,"phases":2199,"primaryCompletion":2200,"completion":2200,"start":2201,"enrollment":1036,"conditions":2202,"interventions":2203},"NCT00061906","Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer",[85],"2006-06","2003-01",[392],[2204],"celecoxib",{"trials":2206,"activeCount":117},[],{"trials":2208,"activeCount":117},[],{"trials":2210,"activeCount":117},[],{"intervention":517,"totalTrials":9,"cells":2212},{"EARLY_PHASE1":2213,"PHASE1":2215,"PHASE2":2217,"PHASE3":2234,"PHASE4":2236,"NA":2238},{"trials":2214,"activeCount":117},[],{"trials":2216,"activeCount":117},[],{"trials":2218,"activeCount":117},[2219,2230],{"nctId":2220,"briefTitle":2221,"status":99,"phases":2222,"primaryCompletion":2223,"completion":2224,"start":2225,"enrollment":2226,"conditions":2227,"interventions":2229},"NCT00201838","Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma",[84,85],"2006-10","2007-05","2001-07",38,[2228,415],"Pancreatic Neoplasms",[517,1749],{"nctId":505,"briefTitle":506,"status":99,"phases":2231,"primaryCompletion":508,"completion":509,"start":510,"enrollment":266,"conditions":2232,"interventions":2233},[85],[512,513,514],[516,517,66],{"trials":2235,"activeCount":117},[],{"trials":2237,"activeCount":117},[],{"trials":2239,"activeCount":117},[],{"intervention":1749,"totalTrials":9,"cells":2241},{"EARLY_PHASE1":2242,"PHASE1":2244,"PHASE2":2250,"PHASE3":2256,"PHASE4":2258,"NA":2260},{"trials":2243,"activeCount":117},[],{"trials":2245,"activeCount":117},[2246],{"nctId":1741,"briefTitle":1742,"status":99,"phases":2247,"primaryCompletion":1744,"completion":1745,"start":1746,"enrollment":589,"conditions":2248,"interventions":2249},[84],[413],[1749,1139,444],{"trials":2251,"activeCount":117},[2252],{"nctId":2220,"briefTitle":2221,"status":99,"phases":2253,"primaryCompletion":2223,"completion":2224,"start":2225,"enrollment":2226,"conditions":2254,"interventions":2255},[84,85],[2228,415],[517,1749],{"trials":2257,"activeCount":117},[],{"trials":2259,"activeCount":117},[],{"trials":2261,"activeCount":117},[],{"intervention":2263,"totalTrials":9,"cells":2264},"erlotinib",{"EARLY_PHASE1":2265,"PHASE1":2267,"PHASE2":2269,"PHASE3":2291,"PHASE4":2293,"NA":2295},{"trials":2266,"activeCount":117},[],{"trials":2268,"activeCount":117},[],{"trials":2270,"activeCount":117},[2271,2282],{"nctId":2272,"briefTitle":2273,"status":99,"phases":2274,"primaryCompletion":2275,"completion":2276,"start":2277,"enrollment":36,"conditions":2278,"interventions":2279},"NCT00834678","Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer",[84,85],"2013-08","2014-09","2009-04",[15],[2280,2263,2281],"bendamustine","Maintenance erlotinib",{"nctId":2283,"briefTitle":2284,"status":99,"phases":2285,"primaryCompletion":2286,"completion":2087,"start":2287,"enrollment":411,"conditions":2288,"interventions":2290},"NCT00230126","OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer",[85],"2011-09","2005-10",[2289],"Carcinoma, Non-Small-Cell Lung",[2263],{"trials":2292,"activeCount":117},[],{"trials":2294,"activeCount":117},[],{"trials":2296,"activeCount":117},[],{"intervention":2298,"totalTrials":9,"cells":2299},"sorafenib",{"EARLY_PHASE1":2300,"PHASE1":2302,"PHASE2":2317,"PHASE3":2328,"PHASE4":2330,"NA":2332},{"trials":2301,"activeCount":117},[],{"trials":2303,"activeCount":117},[2304],{"nctId":2305,"briefTitle":2306,"status":99,"phases":2307,"primaryCompletion":2308,"completion":2309,"start":2310,"enrollment":490,"conditions":2311,"interventions":2314},"NCT00418496","Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma",[84],"2013-02-28","2013-10","2006-11-08",[2312,2313],"Renal Cancer","Melanoma",[2315,2316],"Aldesleukin","Sorafenib",{"trials":2318,"activeCount":117},[2319],{"nctId":2320,"briefTitle":2321,"status":387,"phases":2322,"primaryCompletion":2323,"completion":2323,"start":2324,"enrollment":36,"conditions":2325,"interventions":2327},"NCT00754923","Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer",[85],"2012-04","2008-10",[2326],"Lung Cancer",[2298],{"trials":2329,"activeCount":117},[],{"trials":2331,"activeCount":117},[],{"trials":2333,"activeCount":117},[],{"intervention":1094,"totalTrials":9,"cells":2335},{"EARLY_PHASE1":2336,"PHASE1":2338,"PHASE2":2340,"PHASE3":2350,"PHASE4":2352,"NA":2354},{"trials":2337,"activeCount":117},[],{"trials":2339,"activeCount":117},[],{"trials":2341,"activeCount":117},[2342,2346],{"nctId":1082,"briefTitle":1083,"status":309,"phases":2343,"primaryCompletion":1085,"start":1086,"enrollment":1087,"conditions":2344,"interventions":2345},[85],[1089],[1091,1092,1093,1094,1095,1096,1097,1098,1099,1100,1101,1102,1103,1104],{"nctId":1106,"briefTitle":1107,"status":1108,"phases":2347,"primaryCompletion":1110,"completion":1110,"start":1111,"enrollment":117,"conditions":2348,"interventions":2349},[85],[1113],[1115,1116,1117,1091,1094,629,1103,1104],{"trials":2351,"activeCount":117},[],{"trials":2353,"activeCount":117},[],{"trials":2355,"activeCount":117},[],{"intervention":1099,"totalTrials":9,"cells":2357},{"EARLY_PHASE1":2358,"PHASE1":2360,"PHASE2":2362,"PHASE3":2382,"PHASE4":2384,"NA":2386},{"trials":2359,"activeCount":117},[],{"trials":2361,"activeCount":117},[],{"trials":2363,"activeCount":117},[2364,2368],{"nctId":1082,"briefTitle":1083,"status":309,"phases":2365,"primaryCompletion":1085,"start":1086,"enrollment":1087,"conditions":2366,"interventions":2367},[85],[1089],[1091,1092,1093,1094,1095,1096,1097,1098,1099,1100,1101,1102,1103,1104],{"nctId":2369,"briefTitle":2370,"status":99,"phases":2371,"primaryCompletion":2372,"completion":2373,"start":2374,"enrollment":250,"conditions":2375,"interventions":2379},"NCT01491958","Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation",[85],"2014-01-01","2016-06-27","2011-12-10",[2376,2377,2378],"Acute Myelogenous Leukemia","Acute Lymphocytic Leukemia","Myelodysplastic Syndrome",[2380,2381,1099],"atorvastatin","Tacrolimus",{"trials":2383,"activeCount":117},[],{"trials":2385,"activeCount":117},[],{"trials":2387,"activeCount":117},[],{"intervention":1103,"totalTrials":9,"cells":2389},{"EARLY_PHASE1":2390,"PHASE1":2392,"PHASE2":2394,"PHASE3":2404,"PHASE4":2406,"NA":2408},{"trials":2391,"activeCount":117},[],{"trials":2393,"activeCount":117},[],{"trials":2395,"activeCount":117},[2396,2400],{"nctId":1082,"briefTitle":1083,"status":309,"phases":2397,"primaryCompletion":1085,"start":1086,"enrollment":1087,"conditions":2398,"interventions":2399},[85],[1089],[1091,1092,1093,1094,1095,1096,1097,1098,1099,1100,1101,1102,1103,1104],{"nctId":1106,"briefTitle":1107,"status":1108,"phases":2401,"primaryCompletion":1110,"completion":1110,"start":1111,"enrollment":117,"conditions":2402,"interventions":2403},[85],[1113],[1115,1116,1117,1091,1094,629,1103,1104],{"trials":2405,"activeCount":117},[],{"trials":2407,"activeCount":117},[],{"trials":2409,"activeCount":117},[],{"intervention":1104,"totalTrials":9,"cells":2411},{"EARLY_PHASE1":2412,"PHASE1":2414,"PHASE2":2416,"PHASE3":2426,"PHASE4":2428,"NA":2430},{"trials":2413,"activeCount":117},[],{"trials":2415,"activeCount":117},[],{"trials":2417,"activeCount":117},[2418,2422],{"nctId":1082,"briefTitle":1083,"status":309,"phases":2419,"primaryCompletion":1085,"start":1086,"enrollment":1087,"conditions":2420,"interventions":2421},[85],[1089],[1091,1092,1093,1094,1095,1096,1097,1098,1099,1100,1101,1102,1103,1104],{"nctId":1106,"briefTitle":1107,"status":1108,"phases":2423,"primaryCompletion":1110,"completion":1110,"start":1111,"enrollment":117,"conditions":2424,"interventions":2425},[85],[1113],[1115,1116,1117,1091,1094,629,1103,1104],{"trials":2427,"activeCount":117},[],{"trials":2429,"activeCount":117},[],{"trials":2431,"activeCount":117},[],{"intervention":2177,"totalTrials":9,"cells":2433},{"EARLY_PHASE1":2434,"PHASE1":2436,"PHASE2":2438,"PHASE3":2463,"PHASE4":2465,"NA":2467},{"trials":2435,"activeCount":117},[],{"trials":2437,"activeCount":117},[],{"trials":2439,"activeCount":117},[2440,2459],{"nctId":2441,"briefTitle":2442,"status":99,"phases":2443,"primaryCompletion":2444,"completion":2444,"start":2445,"enrollment":25,"conditions":2446,"interventions":2456},"NCT02760030","Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery",[85],"2025-08-31","2017-02-16",[2447,2448,2449,2450,2451,2452,2453,2454,2455],"Estrogen Receptor and\u002For Progesterone Receptor Positive","HER2\u002FNeu Negative","Stage IA Breast Cancer","Stage IB Breast Cancer","Stage IIA Breast Cancer","Stage IIB Breast Cancer","Stage IIIA Breast Cancer","Stage IIIB Breast Cancer","Stage IIIC Breast Cancer",[2177,2457,2458],"Palbociclib","Aromatase Inhibitors",{"nctId":2170,"briefTitle":2171,"status":99,"phases":2460,"primaryCompletion":2173,"completion":1135,"start":2174,"enrollment":250,"conditions":2461,"interventions":2462},[85],[15],[2152,2177],{"trials":2464,"activeCount":117},[],{"trials":2466,"activeCount":117},[],{"trials":2468,"activeCount":117},[],{"intervention":2470,"totalTrials":9,"cells":2471},"Bortezomib",{"EARLY_PHASE1":2472,"PHASE1":2474,"PHASE2":2484,"PHASE3":2496,"PHASE4":2498,"NA":2500},{"trials":2473,"activeCount":117},[],{"trials":2475,"activeCount":117},[2476],{"nctId":2477,"briefTitle":2478,"status":99,"phases":2479,"primaryCompletion":1724,"completion":1723,"start":2480,"enrollment":19,"conditions":2481,"interventions":2482},"NCT01462773","Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma",[84],"2006-01",[2313],[2470,2483],"Interferon Alfa-2b",{"trials":2485,"activeCount":117},[2486],{"nctId":2487,"briefTitle":2488,"status":99,"phases":2489,"completion":2224,"start":2490,"conditions":2491,"interventions":2494},"NCT00017199","PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors",[85],"2001-04",[2492,2493],"Gastrointestinal Carcinoid Tumor","Islet Cell Tumor",[2495],"bortezomib",{"trials":2497,"activeCount":117},[],{"trials":2499,"activeCount":117},[],{"trials":2501,"activeCount":117},[],{"intervention":417,"totalTrials":9,"cells":2503},{"EARLY_PHASE1":2504,"PHASE1":2506,"PHASE2":2512,"PHASE3":2518,"PHASE4":2520,"NA":2522},{"trials":2505,"activeCount":117},[],{"trials":2507,"activeCount":117},[2508],{"nctId":1755,"briefTitle":1756,"status":1108,"phases":2509,"primaryCompletion":1758,"completion":1758,"start":1758,"enrollment":117,"conditions":2510,"interventions":2511},[84],[1760,1761,1762,1763,1764,1765,1766,1767,1768,1769,1770,1771,1772,1773,1774,1775,1776,1777,1778,1779,1780,1781,1782,1783,1784],[417,1139,1786,1787,1788],{"trials":2513,"activeCount":117},[2514],{"nctId":405,"briefTitle":406,"status":387,"phases":2515,"primaryCompletion":408,"completion":409,"start":410,"enrollment":411,"conditions":2516,"interventions":2517},[84,85],[413,414,415],[417,66,257],{"trials":2519,"activeCount":117},[],{"trials":2521,"activeCount":117},[],{"trials":2523,"activeCount":117},[],{"intervention":2525,"totalTrials":134,"cells":2526},"Interferon Alpha-2b",{"EARLY_PHASE1":2527,"PHASE1":2529,"PHASE2":2531,"PHASE3":2540,"PHASE4":2542,"NA":2544},{"trials":2528,"activeCount":117},[],{"trials":2530,"activeCount":117},[],{"trials":2532,"activeCount":117},[2533],{"nctId":2534,"briefTitle":2535,"status":1108,"phases":2536,"completion":2537,"enrollment":117,"conditions":2538,"interventions":2539},"NCT00293527","Interferon Alpha-2b (Intron A) for Metastatic or Unresectable Clear Cell Renal Carcinoma",[85],"2006-11",[2312],[2525],{"trials":2541,"activeCount":117},[],{"trials":2543,"activeCount":117},[],{"trials":2545,"activeCount":117},[],{"intervention":2547,"totalTrials":134,"cells":2548},"pyrazoloacridine",{"EARLY_PHASE1":2549,"PHASE1":2551,"PHASE2":2553,"PHASE3":2563,"PHASE4":2565,"NA":2567},{"trials":2550,"activeCount":117},[],{"trials":2552,"activeCount":117},[],{"trials":2554,"activeCount":117},[2555],{"nctId":2556,"briefTitle":2557,"status":99,"phases":2558,"completion":2559,"start":2560,"conditions":2561,"interventions":2562},"NCT00003041","Pyrazoloacridine in Treating Women With Refractory Metastatic Breast Cancer",[85],"2002-01","1997-07",[15],[2547],{"trials":2564,"activeCount":117},[],{"trials":2566,"activeCount":117},[],{"trials":2568,"activeCount":117},[],{"intervention":482,"totalTrials":134,"cells":2570},{"EARLY_PHASE1":2571,"PHASE1":2573,"PHASE2":2575,"PHASE3":2581,"PHASE4":2583,"NA":2585},{"trials":2572,"activeCount":117},[],{"trials":2574,"activeCount":117},[],{"trials":2576,"activeCount":117},[2577],{"nctId":470,"briefTitle":471,"status":99,"phases":2578,"primaryCompletion":473,"completion":474,"start":475,"enrollment":476,"conditions":2579,"interventions":2580},[85],[15],[479,480,481,482],{"trials":2582,"activeCount":117},[],{"trials":2584,"activeCount":117},[],{"trials":2586,"activeCount":117},[],{"intervention":710,"totalTrials":134,"cells":2588},{"EARLY_PHASE1":2589,"PHASE1":2591,"PHASE2":2593,"PHASE3":2599,"PHASE4":2601,"NA":2603},{"trials":2590,"activeCount":117},[],{"trials":2592,"activeCount":117},[],{"trials":2594,"activeCount":117},[2595],{"nctId":690,"briefTitle":691,"status":99,"phases":2596,"primaryCompletion":693,"completion":693,"start":694,"enrollment":695,"conditions":2597,"interventions":2598},[84,85],[697,698,699,700,701,702,703,704,705,706,707,708],[710,711,712,713,674],{"trials":2600,"activeCount":117},[],{"trials":2602,"activeCount":117},[],{"trials":2604,"activeCount":117},[],{"intervention":713,"totalTrials":134,"cells":2606},{"EARLY_PHASE1":2607,"PHASE1":2609,"PHASE2":2611,"PHASE3":2617,"PHASE4":2619,"NA":2621},{"trials":2608,"activeCount":117},[],{"trials":2610,"activeCount":117},[],{"trials":2612,"activeCount":117},[2613],{"nctId":690,"briefTitle":691,"status":99,"phases":2614,"primaryCompletion":693,"completion":693,"start":694,"enrollment":695,"conditions":2615,"interventions":2616},[84,85],[697,698,699,700,701,702,703,704,705,706,707,708],[710,711,712,713,674],{"trials":2618,"activeCount":117},[],{"trials":2620,"activeCount":117},[],{"trials":2622,"activeCount":117},[],{"intervention":2624,"totalTrials":134,"cells":2625},"Doxil®",{"EARLY_PHASE1":2626,"PHASE1":2628,"PHASE2":2630,"PHASE3":2641,"PHASE4":2643,"NA":2645},{"trials":2627,"activeCount":117},[],{"trials":2629,"activeCount":117},[],{"trials":2631,"activeCount":117},[2632],{"nctId":2633,"briefTitle":2634,"status":99,"phases":2635,"primaryCompletion":1123,"completion":2141,"start":2636,"enrollment":33,"conditions":2637,"interventions":2638},"NCT00201695","Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma",[85],"2004-07",[1829],[2624,2639,444,2640],"Vincristine","Arsenic Trioxide",{"trials":2642,"activeCount":117},[],{"trials":2644,"activeCount":117},[],{"trials":2646,"activeCount":117},[],{"intervention":2639,"totalTrials":134,"cells":2648},{"EARLY_PHASE1":2649,"PHASE1":2651,"PHASE2":2653,"PHASE3":2659,"PHASE4":2661,"NA":2663},{"trials":2650,"activeCount":117},[],{"trials":2652,"activeCount":117},[],{"trials":2654,"activeCount":117},[2655],{"nctId":2633,"briefTitle":2634,"status":99,"phases":2656,"primaryCompletion":1123,"completion":2141,"start":2636,"enrollment":33,"conditions":2657,"interventions":2658},[85],[1829],[2624,2639,444,2640],{"trials":2660,"activeCount":117},[],{"trials":2662,"activeCount":117},[],{"trials":2664,"activeCount":117},[],{"intervention":2640,"totalTrials":134,"cells":2666},{"EARLY_PHASE1":2667,"PHASE1":2669,"PHASE2":2671,"PHASE3":2677,"PHASE4":2679,"NA":2681},{"trials":2668,"activeCount":117},[],{"trials":2670,"activeCount":117},[],{"trials":2672,"activeCount":117},[2673],{"nctId":2633,"briefTitle":2634,"status":99,"phases":2674,"primaryCompletion":1123,"completion":2141,"start":2636,"enrollment":33,"conditions":2675,"interventions":2676},[85],[1829],[2624,2639,444,2640],{"trials":2678,"activeCount":117},[],{"trials":2680,"activeCount":117},[],{"trials":2682,"activeCount":117},[],{"intervention":2280,"totalTrials":134,"cells":2684},{"EARLY_PHASE1":2685,"PHASE1":2687,"PHASE2":2689,"PHASE3":2695,"PHASE4":2697,"NA":2699},{"trials":2686,"activeCount":117},[],{"trials":2688,"activeCount":117},[],{"trials":2690,"activeCount":117},[2691],{"nctId":2272,"briefTitle":2273,"status":99,"phases":2692,"primaryCompletion":2275,"completion":2276,"start":2277,"enrollment":36,"conditions":2693,"interventions":2694},[84,85],[15],[2280,2263,2281],{"trials":2696,"activeCount":117},[],{"trials":2698,"activeCount":117},[],{"trials":2700,"activeCount":117},[],{"intervention":2281,"totalTrials":134,"cells":2702},{"EARLY_PHASE1":2703,"PHASE1":2705,"PHASE2":2707,"PHASE3":2713,"PHASE4":2715,"NA":2717},{"trials":2704,"activeCount":117},[],{"trials":2706,"activeCount":117},[],{"trials":2708,"activeCount":117},[2709],{"nctId":2272,"briefTitle":2273,"status":99,"phases":2710,"primaryCompletion":2275,"completion":2276,"start":2277,"enrollment":36,"conditions":2711,"interventions":2712},[84,85],[15],[2280,2263,2281],{"trials":2714,"activeCount":117},[],{"trials":2716,"activeCount":117},[],{"trials":2718,"activeCount":117},[],{"intervention":1095,"totalTrials":134,"cells":2720},{"EARLY_PHASE1":2721,"PHASE1":2723,"PHASE2":2725,"PHASE3":2731,"PHASE4":2733,"NA":2735},{"trials":2722,"activeCount":117},[],{"trials":2724,"activeCount":117},[],{"trials":2726,"activeCount":117},[2727],{"nctId":1082,"briefTitle":1083,"status":309,"phases":2728,"primaryCompletion":1085,"start":1086,"enrollment":1087,"conditions":2729,"interventions":2730},[85],[1089],[1091,1092,1093,1094,1095,1096,1097,1098,1099,1100,1101,1102,1103,1104],{"trials":2732,"activeCount":117},[],{"trials":2734,"activeCount":117},[],{"trials":2736,"activeCount":117},[],{"intervention":1096,"totalTrials":134,"cells":2738},{"EARLY_PHASE1":2739,"PHASE1":2741,"PHASE2":2743,"PHASE3":2749,"PHASE4":2751,"NA":2753},{"trials":2740,"activeCount":117},[],{"trials":2742,"activeCount":117},[],{"trials":2744,"activeCount":117},[2745],{"nctId":1082,"briefTitle":1083,"status":309,"phases":2746,"primaryCompletion":1085,"start":1086,"enrollment":1087,"conditions":2747,"interventions":2748},[85],[1089],[1091,1092,1093,1094,1095,1096,1097,1098,1099,1100,1101,1102,1103,1104],{"trials":2750,"activeCount":117},[],{"trials":2752,"activeCount":117},[],{"trials":2754,"activeCount":117},[],{"intervention":1097,"totalTrials":134,"cells":2756},{"EARLY_PHASE1":2757,"PHASE1":2759,"PHASE2":2761,"PHASE3":2767,"PHASE4":2769,"NA":2771},{"trials":2758,"activeCount":117},[],{"trials":2760,"activeCount":117},[],{"trials":2762,"activeCount":117},[2763],{"nctId":1082,"briefTitle":1083,"status":309,"phases":2764,"primaryCompletion":1085,"start":1086,"enrollment":1087,"conditions":2765,"interventions":2766},[85],[1089],[1091,1092,1093,1094,1095,1096,1097,1098,1099,1100,1101,1102,1103,1104],{"trials":2768,"activeCount":117},[],{"trials":2770,"activeCount":117},[],{"trials":2772,"activeCount":117},[],{"intervention":1098,"totalTrials":134,"cells":2774},{"EARLY_PHASE1":2775,"PHASE1":2777,"PHASE2":2779,"PHASE3":2785,"PHASE4":2787,"NA":2789},{"trials":2776,"activeCount":117},[],{"trials":2778,"activeCount":117},[],{"trials":2780,"activeCount":117},[2781],{"nctId":1082,"briefTitle":1083,"status":309,"phases":2782,"primaryCompletion":1085,"start":1086,"enrollment":1087,"conditions":2783,"interventions":2784},[85],[1089],[1091,1092,1093,1094,1095,1096,1097,1098,1099,1100,1101,1102,1103,1104],{"trials":2786,"activeCount":117},[],{"trials":2788,"activeCount":117},[],{"trials":2790,"activeCount":117},[],{"intervention":1101,"totalTrials":134,"cells":2792},{"EARLY_PHASE1":2793,"PHASE1":2795,"PHASE2":2797,"PHASE3":2803,"PHASE4":2805,"NA":2807},{"trials":2794,"activeCount":117},[],{"trials":2796,"activeCount":117},[],{"trials":2798,"activeCount":117},[2799],{"nctId":1082,"briefTitle":1083,"status":309,"phases":2800,"primaryCompletion":1085,"start":1086,"enrollment":1087,"conditions":2801,"interventions":2802},[85],[1089],[1091,1092,1093,1094,1095,1096,1097,1098,1099,1100,1101,1102,1103,1104],{"trials":2804,"activeCount":117},[],{"trials":2806,"activeCount":117},[],{"trials":2808,"activeCount":117},[],{"intervention":1102,"totalTrials":134,"cells":2810},{"EARLY_PHASE1":2811,"PHASE1":2813,"PHASE2":2815,"PHASE3":2821,"PHASE4":2823,"NA":2825},{"trials":2812,"activeCount":117},[],{"trials":2814,"activeCount":117},[],{"trials":2816,"activeCount":117},[2817],{"nctId":1082,"briefTitle":1083,"status":309,"phases":2818,"primaryCompletion":1085,"start":1086,"enrollment":1087,"conditions":2819,"interventions":2820},[85],[1089],[1091,1092,1093,1094,1095,1096,1097,1098,1099,1100,1101,1102,1103,1104],{"trials":2822,"activeCount":117},[],{"trials":2824,"activeCount":117},[],{"trials":2826,"activeCount":117},[],{"intervention":2457,"totalTrials":134,"cells":2828},{"EARLY_PHASE1":2829,"PHASE1":2831,"PHASE2":2833,"PHASE3":2839,"PHASE4":2841,"NA":2843},{"trials":2830,"activeCount":117},[],{"trials":2832,"activeCount":117},[],{"trials":2834,"activeCount":117},[2835],{"nctId":2441,"briefTitle":2442,"status":99,"phases":2836,"primaryCompletion":2444,"completion":2444,"start":2445,"enrollment":25,"conditions":2837,"interventions":2838},[85],[2447,2448,2449,2450,2451,2452,2453,2454,2455],[2177,2457,2458],{"trials":2840,"activeCount":117},[],{"trials":2842,"activeCount":117},[],{"trials":2844,"activeCount":117},[],{"intervention":2458,"totalTrials":134,"cells":2846},{"EARLY_PHASE1":2847,"PHASE1":2849,"PHASE2":2851,"PHASE3":2857,"PHASE4":2859,"NA":2861},{"trials":2848,"activeCount":117},[],{"trials":2850,"activeCount":117},[],{"trials":2852,"activeCount":117},[2853],{"nctId":2441,"briefTitle":2442,"status":99,"phases":2854,"primaryCompletion":2444,"completion":2444,"start":2445,"enrollment":25,"conditions":2855,"interventions":2856},[85],[2447,2448,2449,2450,2451,2452,2453,2454,2455],[2177,2457,2458],{"trials":2858,"activeCount":117},[],{"trials":2860,"activeCount":117},[],{"trials":2862,"activeCount":117},[],{"intervention":1115,"totalTrials":134,"cells":2864},{"EARLY_PHASE1":2865,"PHASE1":2867,"PHASE2":2869,"PHASE3":2875,"PHASE4":2877,"NA":2879},{"trials":2866,"activeCount":117},[],{"trials":2868,"activeCount":117},[],{"trials":2870,"activeCount":117},[2871],{"nctId":1106,"briefTitle":1107,"status":1108,"phases":2872,"primaryCompletion":1110,"completion":1110,"start":1111,"enrollment":117,"conditions":2873,"interventions":2874},[85],[1113],[1115,1116,1117,1091,1094,629,1103,1104],{"trials":2876,"activeCount":117},[],{"trials":2878,"activeCount":117},[],{"trials":2880,"activeCount":117},[],{"intervention":1117,"totalTrials":134,"cells":2882},{"EARLY_PHASE1":2883,"PHASE1":2885,"PHASE2":2887,"PHASE3":2893,"PHASE4":2895,"NA":2897},{"trials":2884,"activeCount":117},[],{"trials":2886,"activeCount":117},[],{"trials":2888,"activeCount":117},[2889],{"nctId":1106,"briefTitle":1107,"status":1108,"phases":2890,"primaryCompletion":1110,"completion":1110,"start":1111,"enrollment":117,"conditions":2891,"interventions":2892},[85],[1113],[1115,1116,1117,1091,1094,629,1103,1104],{"trials":2894,"activeCount":117},[],{"trials":2896,"activeCount":117},[],{"trials":2898,"activeCount":117},[],{"intervention":2900,"totalTrials":134,"cells":2901},"ipilimumab",{"EARLY_PHASE1":2902,"PHASE1":2904,"PHASE2":2906,"PHASE3":2922,"PHASE4":2924,"NA":2926},{"trials":2903,"activeCount":117},[],{"trials":2905,"activeCount":117},[],{"trials":2907,"activeCount":117},[2908],{"nctId":2909,"briefTitle":2910,"status":99,"phases":2911,"primaryCompletion":2912,"completion":2913,"start":2914,"enrollment":525,"conditions":2915,"interventions":2921},"NCT02107755","Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma",[85],"2020-08-03","2021-08-16","2014-09-05",[2916,2917,2918,2919,2920],"Liver Metastases","Lung Metastases","Recurrent Melanoma","Stage IV Melanoma","Tumors Metastatic to Brain",[2900],{"trials":2923,"activeCount":117},[],{"trials":2925,"activeCount":117},[],{"trials":2927,"activeCount":117},[],{"intervention":1864,"totalTrials":134,"cells":2929},{"EARLY_PHASE1":2930,"PHASE1":2932,"PHASE2":2934,"PHASE3":2940,"PHASE4":2942,"NA":2944},{"trials":2931,"activeCount":117},[],{"trials":2933,"activeCount":117},[],{"trials":2935,"activeCount":117},[2936],{"nctId":1845,"briefTitle":1846,"status":99,"phases":2937,"primaryCompletion":1848,"completion":1848,"start":1849,"enrollment":1850,"conditions":2938,"interventions":2939},[85],[1852,1853,1854,1855,1072,1856,1857,1858,1859,1860,1861,1862],[1864,1816],{"trials":2941,"activeCount":117},[],{"trials":2943,"activeCount":117},[],{"trials":2945,"activeCount":117},[],{"intervention":1804,"totalTrials":134,"cells":2947},{"EARLY_PHASE1":2948,"PHASE1":2950,"PHASE2":2952,"PHASE3":2958,"PHASE4":2960,"NA":2962},{"trials":2949,"activeCount":117},[],{"trials":2951,"activeCount":117},[],{"trials":2953,"activeCount":117},[2954],{"nctId":1792,"briefTitle":1793,"status":99,"phases":2955,"primaryCompletion":1795,"start":1796,"enrollment":92,"conditions":2956,"interventions":2957},[85],[1798,1799,1800,1801,1802],[1804,582],{"trials":2959,"activeCount":117},[],{"trials":2961,"activeCount":117},[],{"trials":2963,"activeCount":117},[],{"intervention":2965,"totalTrials":134,"cells":2966},"Melphalan Hydrochloride",{"EARLY_PHASE1":2967,"PHASE1":2969,"PHASE2":2971,"PHASE3":2983,"PHASE4":2985,"NA":2987},{"trials":2968,"activeCount":117},[],{"trials":2970,"activeCount":117},[],{"trials":2972,"activeCount":117},[2973],{"nctId":2974,"briefTitle":2975,"status":1108,"phases":2976,"primaryCompletion":2977,"completion":2977,"start":2978,"enrollment":117,"conditions":2979,"interventions":2982},"NCT03328936","Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant",[85],"2021-03-31","2018-09-01",[697,2980,2981],"Recurrent Plasma Cell Myeloma","Refractory Plasma Cell Myeloma",[2965,2965],{"trials":2984,"activeCount":117},[],{"trials":2986,"activeCount":117},[],{"trials":2988,"activeCount":117},[],{"intervention":2990,"totalTrials":134,"cells":2991},"Dietary Intervention",{"EARLY_PHASE1":2992,"PHASE1":2994,"PHASE2":2996,"PHASE3":3006,"PHASE4":3008,"NA":3010},{"trials":2993,"activeCount":117},[],{"trials":2995,"activeCount":117},[],{"trials":2997,"activeCount":117},[2998],{"nctId":2999,"briefTitle":3000,"status":99,"phases":3001,"primaryCompletion":3002,"completion":3002,"start":3003,"enrollment":1036,"conditions":3004,"interventions":3005},"NCT03654638","Soy Bread Diet in Improving Immune Function in Participants With Prostate Cancer",[85],"2022-03-09","2018-08-15",[891],[2990,2990],{"trials":3007,"activeCount":117},[],{"trials":3009,"activeCount":117},[],{"trials":3011,"activeCount":117},[],{"intervention":3013,"totalTrials":134,"cells":3014},"Infliximab",{"EARLY_PHASE1":3015,"PHASE1":3017,"PHASE2":3019,"PHASE3":3030,"PHASE4":3032,"NA":3034},{"trials":3016,"activeCount":117},[],{"trials":3018,"activeCount":117},[],{"trials":3020,"activeCount":117},[3021],{"nctId":3022,"briefTitle":3023,"status":99,"phases":3024,"primaryCompletion":3025,"completion":3026,"start":3027,"enrollment":695,"conditions":3028,"interventions":3029},"NCT00201799","Infliximab for the Prevention of Graft-versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplantation",[85],"2006-08","2008-03","2004-02",[2090],[3013],{"trials":3031,"activeCount":117},[],{"trials":3033,"activeCount":117},[],{"trials":3035,"activeCount":117},[],{"intervention":3037,"totalTrials":134,"cells":3038},"minocycline hydrochloride",{"EARLY_PHASE1":3039,"PHASE1":3041,"PHASE2":3043,"PHASE3":3057,"PHASE4":3059,"NA":3061},{"trials":3040,"activeCount":117},[],{"trials":3042,"activeCount":117},[],{"trials":3044,"activeCount":117},[3045],{"nctId":3046,"briefTitle":3047,"status":99,"phases":3048,"primaryCompletion":3049,"completion":3049,"start":3050,"enrollment":1136,"conditions":3051,"interventions":3056},"NCT02203552","Minocycline Hydrochloride in Reducing Chemotherapy Induced Depression and Anxiety in Patients With Stage I-III Breast Cancer",[85],"2020-06-15","2015-06-23",[3052,3053,3054,2449,2450,3055,2453,2454,2455],"Anxiety Disorder","Depression","Recurrent Breast Cancer","Stage II Breast Cancer",[3037],{"trials":3058,"activeCount":117},[],{"trials":3060,"activeCount":117},[],{"trials":3062,"activeCount":117},[],{"intervention":3064,"totalTrials":134,"cells":3065},"chemoprevention",{"EARLY_PHASE1":3066,"PHASE1":3068,"PHASE2":3070,"PHASE3":3115,"PHASE4":3117,"NA":3119},{"trials":3067,"activeCount":117},[],{"trials":3069,"activeCount":117},[],{"trials":3071,"activeCount":117},[3072],{"nctId":3073,"briefTitle":3074,"status":99,"phases":3075,"primaryCompletion":3076,"completion":3076,"start":3077,"enrollment":889,"conditions":3078,"interventions":3114},"NCT01469429","Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.",[84,85],"2014-09-17","2007-09-04",[543,554,3079,3080,3081,3082,3083,3084,3085,3086,3087,3088,3089,3090,3091,3092,3093,3094,3095,3096,3097,3098,3099,3100,3101,3102,3103,3104,3105,3106,3107,591,3108,3109,555,556,557,558,559,560,3110,562,563,564,565,566,567,3111,569,570,571,572,3112,574,3113,576,577,578],"Stage 0 Hypopharyngeal Cancer","Stage 0 Laryngeal Cancer","Stage 0 Lip and Oral Cavity Cancer","Stage 0 Nasopharyngeal Cancer","Stage 0 Oropharyngeal Cancer","Stage 0 Paranasal Sinus and Nasal Cavity Cancer","Stage I Salivary Gland Cancer","Stage I Squamous Cell Carcinoma of the Hypopharynx","Stage I Squamous Cell Carcinoma of the Larynx","Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage I Squamous Cell Carcinoma of the Nasopharynx","Stage I Squamous Cell Carcinoma of the Oropharynx","Stage I Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage I Verrucous Carcinoma of the Larynx","Stage I Verrucous Carcinoma of the Oral Cavity","Stage II Salivary Gland Cancer","Stage II Squamous Cell Carcinoma of the Hypopharynx","Stage II Squamous Cell Carcinoma of the Larynx","Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage II Squamous Cell Carcinoma of the Nasopharynx","Stage II Squamous Cell Carcinoma of the Oropharynx","Stage II Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage II Verrucous Carcinoma of the Larynx","Stage II Verrucous Carcinoma of the Oral Cavity","Stage III Salivary Gland Cancer","Stage III Squamous Cell Carcinoma of the Hypopharynx","Stage III Squamous Cell Carcinoma of the Larynx","Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage III Squamous Cell Carcinoma of the Nasopharynx","Stage III Verrucous Carcinoma of the Larynx","Stage III Verrucous Carcinoma of the Oral Cavity","Stage IVA Nasal Cavity and Paranasal Sinus Cancer","Stage IVB Oral Cavity Squamous Cell Carcinoma","Stage IVC Oral Cavity Squamous Cell Carcinoma","Paranasal Sinus and Nasal Cavity Squamous Cell Carcinoma",[3064,3064],{"trials":3116,"activeCount":117},[],{"trials":3118,"activeCount":117},[],{"trials":3120,"activeCount":117},[],{"intervention":1718,"totalTrials":134,"cells":3122},{"EARLY_PHASE1":3123,"PHASE1":3125,"PHASE2":3127,"PHASE3":3133,"PHASE4":3135,"NA":3137},{"trials":3124,"activeCount":117},[],{"trials":3126,"activeCount":117},[],{"trials":3128,"activeCount":117},[3129],{"nctId":1704,"briefTitle":1705,"status":387,"phases":3130,"primaryCompletion":1707,"completion":539,"start":1708,"enrollment":25,"conditions":3131,"interventions":3132},[85],[1710,1711,1712,1713,699,700,701,1714,702,1715,1716],[1718,1116],{"trials":3134,"activeCount":117},[],{"trials":3136,"activeCount":117},[],{"trials":3138,"activeCount":117},[],{"intervention":1140,"totalTrials":134,"cells":3140},{"EARLY_PHASE1":3141,"PHASE1":3143,"PHASE2":3145,"PHASE3":3151,"PHASE4":3153,"NA":3155},{"trials":3142,"activeCount":117},[],{"trials":3144,"activeCount":117},[],{"trials":3146,"activeCount":117},[3147],{"nctId":1131,"briefTitle":1132,"status":99,"phases":3148,"primaryCompletion":1134,"completion":1135,"start":489,"enrollment":1136,"conditions":3149,"interventions":3150},[85],[15],[1139,1140,1052],{"trials":3152,"activeCount":117},[],{"trials":3154,"activeCount":117},[],{"trials":3156,"activeCount":117},[],{"intervention":3158,"totalTrials":134,"cells":3159},"CPT-11",{"EARLY_PHASE1":3160,"PHASE1":3162,"PHASE2":3164,"PHASE3":3179,"PHASE4":3181,"NA":3183},{"trials":3161,"activeCount":117},[],{"trials":3163,"activeCount":117},[],{"trials":3165,"activeCount":117},[3166],{"nctId":3167,"briefTitle":3168,"status":99,"phases":3169,"primaryCompletion":2223,"completion":3170,"start":3171,"enrollment":1555,"conditions":3172,"interventions":3177},"NCT00201747","Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer",[85],"2010-02","2001-09",[3173,3174,3175,3176],"Esophageal Cancer","Esophagus Cancer","Cancer of Stomach","Stomach Cancer",[3158,3178],"Mitomycin C",{"trials":3180,"activeCount":117},[],{"trials":3182,"activeCount":117},[],{"trials":3184,"activeCount":117},[],{"intervention":3178,"totalTrials":134,"cells":3186},{"EARLY_PHASE1":3187,"PHASE1":3189,"PHASE2":3191,"PHASE3":3197,"PHASE4":3199,"NA":3201},{"trials":3188,"activeCount":117},[],{"trials":3190,"activeCount":117},[],{"trials":3192,"activeCount":117},[3193],{"nctId":3167,"briefTitle":3168,"status":99,"phases":3194,"primaryCompletion":2223,"completion":3170,"start":3171,"enrollment":1555,"conditions":3195,"interventions":3196},[85],[3173,3174,3175,3176],[3158,3178],{"trials":3198,"activeCount":117},[],{"trials":3200,"activeCount":117},[],{"trials":3202,"activeCount":117},[],{"intervention":868,"totalTrials":134,"cells":3204},{"EARLY_PHASE1":3205,"PHASE1":3207,"PHASE2":3209,"PHASE3":3215,"PHASE4":3217,"NA":3219},{"trials":3206,"activeCount":117},[],{"trials":3208,"activeCount":117},[],{"trials":3210,"activeCount":117},[3211],{"nctId":856,"briefTitle":857,"status":387,"phases":3212,"primaryCompletion":859,"completion":859,"start":860,"enrollment":33,"conditions":3213,"interventions":3214},[84,85],[862,863,864,865,866],[73,868],{"trials":3216,"activeCount":117},[],{"trials":3218,"activeCount":117},[],{"trials":3220,"activeCount":117},[],{"intervention":2380,"totalTrials":134,"cells":3222},{"EARLY_PHASE1":3223,"PHASE1":3225,"PHASE2":3227,"PHASE3":3233,"PHASE4":3235,"NA":3237},{"trials":3224,"activeCount":117},[],{"trials":3226,"activeCount":117},[],{"trials":3228,"activeCount":117},[3229],{"nctId":2369,"briefTitle":2370,"status":99,"phases":3230,"primaryCompletion":2372,"completion":2373,"start":2374,"enrollment":250,"conditions":3231,"interventions":3232},[85],[2376,2377,2378],[2380,2381,1099],{"trials":3234,"activeCount":117},[],{"trials":3236,"activeCount":117},[],{"trials":3238,"activeCount":117},[],{"intervention":2381,"totalTrials":134,"cells":3240},{"EARLY_PHASE1":3241,"PHASE1":3243,"PHASE2":3245,"PHASE3":3251,"PHASE4":3253,"NA":3255},{"trials":3242,"activeCount":117},[],{"trials":3244,"activeCount":117},[],{"trials":3246,"activeCount":117},[3247],{"nctId":2369,"briefTitle":2370,"status":99,"phases":3248,"primaryCompletion":2372,"completion":2373,"start":2374,"enrollment":250,"conditions":3249,"interventions":3250},[85],[2376,2377,2378],[2380,2381,1099],{"trials":3252,"activeCount":117},[],{"trials":3254,"activeCount":117},[],{"trials":3256,"activeCount":117},[],{"intervention":3258,"totalTrials":134,"cells":3259},"Letermovir",{"EARLY_PHASE1":3260,"PHASE1":3262,"PHASE2":3264,"PHASE3":3279,"PHASE4":3281,"NA":3283},{"trials":3261,"activeCount":117},[],{"trials":3263,"activeCount":117},[],{"trials":3265,"activeCount":117},[3266],{"nctId":3267,"briefTitle":3268,"status":99,"phases":3269,"primaryCompletion":3270,"completion":3271,"start":3272,"enrollment":92,"conditions":3273,"interventions":3278},"NCT04312841","Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab",[85],"2023-11-24","2024-04-09","2020-09-15",[3274,671,1165,3275,3276,3277],"B-Cell Prolymphocytic Leukemia","Primary Cutaneous T-Cell Non-Hodgkin Lymphoma","Sezary Syndrome","T-Cell Prolymphocytic Leukemia",[3258],{"trials":3280,"activeCount":117},[],{"trials":3282,"activeCount":117},[],{"trials":3284,"activeCount":117},[],{"intervention":3286,"totalTrials":134,"cells":3287},"Clofarabine",{"EARLY_PHASE1":3288,"PHASE1":3290,"PHASE2":3292,"PHASE3":3301,"PHASE4":3303,"NA":3305},{"trials":3289,"activeCount":117},[],{"trials":3291,"activeCount":117},[],{"trials":3293,"activeCount":117},[3294],{"nctId":3295,"briefTitle":3296,"status":99,"phases":3297,"primaryCompletion":3298,"completion":2200,"start":489,"enrollment":92,"conditions":3299,"interventions":3300},"NCT00201669","A Phase II Study of Clofarabine in Patients With Aggressive Non-Hodgkin's Lymphoma",[85],"2006-05",[1691],[3286],{"trials":3302,"activeCount":117},[],{"trials":3304,"activeCount":117},[],{"trials":3306,"activeCount":117},[],{"intervention":3308,"totalTrials":134,"cells":3309},"General Anesthesia Procedure",{"EARLY_PHASE1":3310,"PHASE1":3312,"PHASE2":3314,"PHASE3":3325,"PHASE4":3327,"NA":3329},{"trials":3311,"activeCount":117},[],{"trials":3313,"activeCount":117},[],{"trials":3315,"activeCount":117},[3316],{"nctId":3317,"briefTitle":3318,"status":387,"phases":3319,"primaryCompletion":3320,"completion":3320,"start":3321,"enrollment":525,"conditions":3322,"interventions":3324},"NCT04992507","Impact of Total Intravenous Anesthesia Following Cancer Surgery, TIVACS Study",[85],"2024-01-26","2023-06-02",[3323],"Pancreatic Adenocarcinoma",[3308],{"trials":3326,"activeCount":117},[],{"trials":3328,"activeCount":117},[],{"trials":3330,"activeCount":117},[],{"intervention":3332,"totalTrials":134,"cells":3333},"Daratumumab",{"EARLY_PHASE1":3334,"PHASE1":3336,"PHASE2":3338,"PHASE3":3349,"PHASE4":3351,"NA":3353},{"trials":3335,"activeCount":117},[],{"trials":3337,"activeCount":117},[],{"trials":3339,"activeCount":117},[3340],{"nctId":3341,"briefTitle":3342,"status":99,"phases":3343,"primaryCompletion":3344,"completion":3344,"start":3345,"enrollment":320,"conditions":3346,"interventions":3348},"NCT02944565","Daratumumab in Treating Patients With Multiple Myeloma",[85],"2017-07-20","2017-02-22",[3347],"Plasma Cell Myeloma",[3332],{"trials":3350,"activeCount":117},[],{"trials":3352,"activeCount":117},[],{"trials":3354,"activeCount":117},[],{"intervention":3356,"totalTrials":134,"cells":3357},"chloroquinoxaline sulfonamide",{"EARLY_PHASE1":3358,"PHASE1":3360,"PHASE2":3362,"PHASE3":3372,"PHASE4":3374,"NA":3376},{"trials":3359,"activeCount":117},[],{"trials":3361,"activeCount":117},[],{"trials":3363,"activeCount":117},[3364],{"nctId":3365,"briefTitle":3366,"status":99,"phases":3367,"completion":3027,"start":3368,"conditions":3369,"interventions":3371},"NCT00005864","Chloroquinoxaline Sulfonamide in Treating Patients With Stage IV Colorectal Cancer",[85],"2000-04",[3370],"Colorectal Cancer",[3356],{"trials":3373,"activeCount":117},[],{"trials":3375,"activeCount":117},[],{"trials":3377,"activeCount":117},[],{"intervention":1879,"totalTrials":134,"cells":3379},{"EARLY_PHASE1":3380,"PHASE1":3382,"PHASE2":3384,"PHASE3":3390,"PHASE4":3392,"NA":3394},{"trials":3381,"activeCount":117},[],{"trials":3383,"activeCount":117},[],{"trials":3385,"activeCount":117},[3386],{"nctId":1866,"briefTitle":1867,"status":99,"phases":3387,"primaryCompletion":1869,"completion":1869,"start":1870,"enrollment":1062,"conditions":3388,"interventions":3389},[85],[1872,1873,1874,1875,1876,1877],[1879,1816],{"trials":3391,"activeCount":117},[],{"trials":3393,"activeCount":117},[],{"trials":3395,"activeCount":117},[],{"intervention":1253,"totalTrials":134,"cells":3397},{"EARLY_PHASE1":3398,"PHASE1":3400,"PHASE2":3402,"PHASE3":3408,"PHASE4":3410,"NA":3412},{"trials":3399,"activeCount":117},[],{"trials":3401,"activeCount":117},[],{"trials":3403,"activeCount":117},[3404],{"nctId":1241,"briefTitle":1242,"status":99,"phases":3405,"primaryCompletion":1244,"completion":1244,"start":1245,"enrollment":92,"conditions":3406,"interventions":3407},[85],[1247,1248,1249,1250,1251],[81,1253],{"trials":3409,"activeCount":117},[],{"trials":3411,"activeCount":117},[],{"trials":3413,"activeCount":117},[],{"intervention":594,"totalTrials":541,"cells":3415},{"EARLY_PHASE1":3416,"PHASE1":3418,"PHASE2":3437,"PHASE3":3439,"PHASE4":3441,"NA":3443},{"trials":3417,"activeCount":117},[],{"trials":3419,"activeCount":117},[3420,3429,3433],{"nctId":3421,"briefTitle":3422,"status":99,"phases":3423,"primaryCompletion":3424,"completion":3425,"start":408,"enrollment":16,"conditions":3426,"interventions":3428},"NCT00561418","Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma",[84],"2012-11","2013-05",[1113,3427],"Small Intestine Cancer",[594],{"nctId":1833,"briefTitle":1834,"status":99,"phases":3430,"primaryCompletion":1836,"completion":1837,"start":1838,"enrollment":695,"conditions":3431,"interventions":3432},[84],[1829,1840],[1816,594],{"nctId":584,"briefTitle":585,"status":99,"phases":3434,"primaryCompletion":587,"completion":587,"start":588,"enrollment":589,"conditions":3435,"interventions":3436},[84],[591,592],[594,380],{"trials":3438,"activeCount":117},[],{"trials":3440,"activeCount":117},[],{"trials":3442,"activeCount":117},[],{"trials":3444,"activeCount":117},[],{"intervention":3446,"totalTrials":9,"cells":3447},"fluorouracil",{"EARLY_PHASE1":3448,"PHASE1":3450,"PHASE2":3472,"PHASE3":3474,"PHASE4":3476,"NA":3478},{"trials":3449,"activeCount":117},[],{"trials":3451,"activeCount":117},[3452,3468],{"nctId":3453,"briefTitle":3454,"status":99,"phases":3455,"primaryCompletion":3456,"completion":3456,"start":3457,"enrollment":695,"conditions":3458,"interventions":3466},"NCT01740648","Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer",[84],"2021-09-29","2012-11-26",[3459,3460,3461,3462,3463,3464,3465],"Recurrent Rectal Cancer","Stage IIA Rectal Cancer","Stage IIB Rectal Cancer","Stage IIC Rectal Cancer","Stage IIIA Rectal Cancer","Stage IIIB Rectal Cancer","Stage IIIC Rectal Cancer",[3467,3446],"trametinib",{"nctId":1755,"briefTitle":1756,"status":1108,"phases":3469,"primaryCompletion":1758,"completion":1758,"start":1758,"enrollment":117,"conditions":3470,"interventions":3471},[84],[1760,1761,1762,1763,1764,1765,1766,1767,1768,1769,1770,1771,1772,1773,1774,1775,1776,1777,1778,1779,1780,1781,1782,1783,1784],[417,1139,1786,1787,1788],{"trials":3473,"activeCount":117},[],{"trials":3475,"activeCount":117},[],{"trials":3477,"activeCount":117},[],{"trials":3479,"activeCount":117},[],{"intervention":1167,"totalTrials":9,"cells":3481},{"EARLY_PHASE1":3482,"PHASE1":3484,"PHASE2":3497,"PHASE3":3499,"PHASE4":3501,"NA":3503},{"trials":3483,"activeCount":117},[],{"trials":3485,"activeCount":117},[3486,3490],{"nctId":1154,"briefTitle":1155,"status":99,"phases":3487,"primaryCompletion":1157,"completion":1158,"start":1159,"enrollment":16,"conditions":3488,"interventions":3489},[84],[1161,1162,1163,1164,1165],[1167,1168,1078,1169],{"nctId":3491,"briefTitle":3492,"status":99,"phases":3493,"completion":3025,"start":2559,"conditions":3494,"interventions":3495},"NCT00024180","FR901228 in Treating Patients With Hematologic Cancer",[84],[1089,1113],[3496],"romidepsin",{"trials":3498,"activeCount":117},[],{"trials":3500,"activeCount":117},[],{"trials":3502,"activeCount":117},[],{"trials":3504,"activeCount":117},[],{"intervention":1831,"totalTrials":134,"cells":3506},{"EARLY_PHASE1":3507,"PHASE1":3509,"PHASE2":3515,"PHASE3":3517,"PHASE4":3519,"NA":3521},{"trials":3508,"activeCount":117},[],{"trials":3510,"activeCount":117},[3511],{"nctId":1823,"briefTitle":1824,"status":387,"phases":3512,"primaryCompletion":1826,"completion":1826,"start":1827,"enrollment":155,"conditions":3513,"interventions":3514},[84],[1829],[1816,1831],{"trials":3516,"activeCount":117},[],{"trials":3518,"activeCount":117},[],{"trials":3520,"activeCount":117},[],{"trials":3522,"activeCount":117},[],{"intervention":3524,"totalTrials":134,"cells":3525},"Dulbecco''s Phosphate-Buffered Saline",{"EARLY_PHASE1":3526,"PHASE1":3528,"PHASE2":3546,"PHASE3":3548,"PHASE4":3550,"NA":3552},{"trials":3527,"activeCount":117},[],{"trials":3529,"activeCount":117},[3530],{"nctId":3531,"briefTitle":3532,"status":3533,"phases":3534,"primaryCompletion":3535,"completion":144,"start":3536,"enrollment":114,"conditions":3537,"interventions":3543},"NCT06741072","BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants","SUSPENDED",[84],"2027-07-31","2026-07-15",[3538,3539,3540,3541,3542],"Chronic Kidney Disease, Stage 4","Chronic Kidney Disease, Stage 5","EBV-Related Lymphoproliferative Disorder","EBV-Related Malignant Neoplasm","Post-Transplant Lymphoproliferative Disorder",[3524,3544,3545],"Peptide Vaccine","QS21",{"trials":3547,"activeCount":117},[],{"trials":3549,"activeCount":117},[],{"trials":3551,"activeCount":117},[],{"trials":3553,"activeCount":117},[],{"intervention":3544,"totalTrials":134,"cells":3555},{"EARLY_PHASE1":3556,"PHASE1":3558,"PHASE2":3564,"PHASE3":3566,"PHASE4":3568,"NA":3570},{"trials":3557,"activeCount":117},[],{"trials":3559,"activeCount":117},[3560],{"nctId":3531,"briefTitle":3532,"status":3533,"phases":3561,"primaryCompletion":3535,"completion":144,"start":3536,"enrollment":114,"conditions":3562,"interventions":3563},[84],[3538,3539,3540,3541,3542],[3524,3544,3545],{"trials":3565,"activeCount":117},[],{"trials":3567,"activeCount":117},[],{"trials":3569,"activeCount":117},[],{"trials":3571,"activeCount":117},[],{"intervention":3545,"totalTrials":134,"cells":3573},{"EARLY_PHASE1":3574,"PHASE1":3576,"PHASE2":3582,"PHASE3":3584,"PHASE4":3586,"NA":3588},{"trials":3575,"activeCount":117},[],{"trials":3577,"activeCount":117},[3578],{"nctId":3531,"briefTitle":3532,"status":3533,"phases":3579,"primaryCompletion":3535,"completion":144,"start":3536,"enrollment":114,"conditions":3580,"interventions":3581},[84],[3538,3539,3540,3541,3542],[3524,3544,3545],{"trials":3583,"activeCount":117},[],{"trials":3585,"activeCount":117},[],{"trials":3587,"activeCount":117},[],{"trials":3589,"activeCount":117},[],{"intervention":3591,"totalTrials":134,"cells":3592},"Mirvetuximab Soravtansine",{"EARLY_PHASE1":3593,"PHASE1":3595,"PHASE2":3617,"PHASE3":3619,"PHASE4":3621,"NA":3623},{"trials":3594,"activeCount":117},[],{"trials":3596,"activeCount":117},[3597],{"nctId":3598,"briefTitle":3599,"status":99,"phases":3600,"primaryCompletion":3601,"completion":3602,"start":3603,"enrollment":1036,"conditions":3604,"interventions":3615},"NCT03552471","Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer",[84],"2022-06-24","2022-12-19","2018-07-12",[3605,3606,3607,3608,3609,3610,3611,3612,3613,3614],"BRCA1 Gene Mutation","BRCA2 Gene Mutation","Folate Receptor Alpha Positive","Recurrent Fallopian Tube Carcinoma","Recurrent Ovarian Carcinoma","Recurrent Primary Peritoneal Carcinoma","Recurrent Uterine Corpus Carcinoma","Recurrent Uterine Serous Carcinoma","Recurrent Uterine Carcinosarcoma","Platinum Resistant Ovarian Cancer",[3591,3616],"Rucaparib Camsylate",{"trials":3618,"activeCount":117},[],{"trials":3620,"activeCount":117},[],{"trials":3622,"activeCount":117},[],{"trials":3624,"activeCount":117},[],{"intervention":3616,"totalTrials":134,"cells":3626},{"EARLY_PHASE1":3627,"PHASE1":3629,"PHASE2":3635,"PHASE3":3637,"PHASE4":3639,"NA":3641},{"trials":3628,"activeCount":117},[],{"trials":3630,"activeCount":117},[3631],{"nctId":3598,"briefTitle":3599,"status":99,"phases":3632,"primaryCompletion":3601,"completion":3602,"start":3603,"enrollment":1036,"conditions":3633,"interventions":3634},[84],[3605,3606,3607,3608,3609,3610,3611,3612,3613,3614],[3591,3616],{"trials":3636,"activeCount":117},[],{"trials":3638,"activeCount":117},[],{"trials":3640,"activeCount":117},[],{"trials":3642,"activeCount":117},[],{"intervention":3467,"totalTrials":134,"cells":3644},{"EARLY_PHASE1":3645,"PHASE1":3647,"PHASE2":3653,"PHASE3":3655,"PHASE4":3657,"NA":3659},{"trials":3646,"activeCount":117},[],{"trials":3648,"activeCount":117},[3649],{"nctId":3453,"briefTitle":3454,"status":99,"phases":3650,"primaryCompletion":3456,"completion":3456,"start":3457,"enrollment":695,"conditions":3651,"interventions":3652},[84],[3459,3460,3461,3462,3463,3464,3465],[3467,3446],{"trials":3654,"activeCount":117},[],{"trials":3656,"activeCount":117},[],{"trials":3658,"activeCount":117},[],{"trials":3660,"activeCount":117},[],{"intervention":1168,"totalTrials":134,"cells":3662},{"EARLY_PHASE1":3663,"PHASE1":3665,"PHASE2":3671,"PHASE3":3673,"PHASE4":3675,"NA":3677},{"trials":3664,"activeCount":117},[],{"trials":3666,"activeCount":117},[3667],{"nctId":1154,"briefTitle":1155,"status":99,"phases":3668,"primaryCompletion":1157,"completion":1158,"start":1159,"enrollment":16,"conditions":3669,"interventions":3670},[84],[1161,1162,1163,1164,1165],[1167,1168,1078,1169],{"trials":3672,"activeCount":117},[],{"trials":3674,"activeCount":117},[],{"trials":3676,"activeCount":117},[],{"trials":3678,"activeCount":117},[],{"intervention":1169,"totalTrials":134,"cells":3680},{"EARLY_PHASE1":3681,"PHASE1":3683,"PHASE2":3689,"PHASE3":3691,"PHASE4":3693,"NA":3695},{"trials":3682,"activeCount":117},[],{"trials":3684,"activeCount":117},[3685],{"nctId":1154,"briefTitle":1155,"status":99,"phases":3686,"primaryCompletion":1157,"completion":1158,"start":1159,"enrollment":16,"conditions":3687,"interventions":3688},[84],[1161,1162,1163,1164,1165],[1167,1168,1078,1169],{"trials":3690,"activeCount":117},[],{"trials":3692,"activeCount":117},[],{"trials":3694,"activeCount":117},[],{"trials":3696,"activeCount":117},[],{"intervention":2483,"totalTrials":134,"cells":3698},{"EARLY_PHASE1":3699,"PHASE1":3701,"PHASE2":3707,"PHASE3":3709,"PHASE4":3711,"NA":3713},{"trials":3700,"activeCount":117},[],{"trials":3702,"activeCount":117},[3703],{"nctId":2477,"briefTitle":2478,"status":99,"phases":3704,"primaryCompletion":1724,"completion":1723,"start":2480,"enrollment":19,"conditions":3705,"interventions":3706},[84],[2313],[2470,2483],{"trials":3708,"activeCount":117},[],{"trials":3710,"activeCount":117},[],{"trials":3712,"activeCount":117},[],{"trials":3714,"activeCount":117},[],{"intervention":581,"totalTrials":134,"cells":3716},{"EARLY_PHASE1":3717,"PHASE1":3719,"PHASE2":3725,"PHASE3":3727,"PHASE4":3729,"NA":3731},{"trials":3718,"activeCount":117},[],{"trials":3720,"activeCount":117},[3721],{"nctId":536,"briefTitle":537,"status":99,"phases":3722,"primaryCompletion":539,"completion":539,"start":540,"enrollment":541,"conditions":3723,"interventions":3724},[84],[543,544,545,546,547,548,549,550,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,576,577,578,579],[581,380,582],{"trials":3726,"activeCount":117},[],{"trials":3728,"activeCount":117},[],{"trials":3730,"activeCount":117},[],{"trials":3732,"activeCount":117},[],{"intervention":2031,"totalTrials":134,"cells":3734},{"EARLY_PHASE1":3735,"PHASE1":3737,"PHASE2":3743,"PHASE3":3745,"PHASE4":3747,"NA":3749},{"trials":3736,"activeCount":117},[],{"trials":3738,"activeCount":117},[3739],{"nctId":2024,"briefTitle":2025,"status":99,"phases":3740,"primaryCompletion":2027,"completion":2028,"start":599,"enrollment":1062,"conditions":3741,"interventions":3742},[84],[1691],[2031,1187],{"trials":3744,"activeCount":117},[],{"trials":3746,"activeCount":117},[],{"trials":3748,"activeCount":117},[],{"trials":3750,"activeCount":117},[],{"intervention":371,"totalTrials":134,"cells":3752},{"EARLY_PHASE1":3753,"PHASE1":3755,"PHASE2":3761,"PHASE3":3763,"PHASE4":3765,"NA":3767},{"trials":3754,"activeCount":117},[],{"trials":3756,"activeCount":117},[3757],{"nctId":346,"briefTitle":347,"status":99,"phases":3758,"primaryCompletion":349,"completion":350,"start":351,"enrollment":36,"conditions":3759,"interventions":3760},[84],[29,353,354,18,355,356,21,357,358,359,360,361,362,363,364,365,366,367,368,369],[371,372,257],{"trials":3762,"activeCount":117},[],{"trials":3764,"activeCount":117},[],{"trials":3766,"activeCount":117},[],{"trials":3768,"activeCount":117},[],{"intervention":372,"totalTrials":134,"cells":3770},{"EARLY_PHASE1":3771,"PHASE1":3773,"PHASE2":3779,"PHASE3":3781,"PHASE4":3783,"NA":3785},{"trials":3772,"activeCount":117},[],{"trials":3774,"activeCount":117},[3775],{"nctId":346,"briefTitle":347,"status":99,"phases":3776,"primaryCompletion":349,"completion":350,"start":351,"enrollment":36,"conditions":3777,"interventions":3778},[84],[29,353,354,18,355,356,21,357,358,359,360,361,362,363,364,365,366,367,368,369],[371,372,257],{"trials":3780,"activeCount":117},[],{"trials":3782,"activeCount":117},[],{"trials":3784,"activeCount":117},[],{"trials":3786,"activeCount":117},[],{"intervention":1900,"totalTrials":134,"cells":3788},{"EARLY_PHASE1":3789,"PHASE1":3791,"PHASE2":3797,"PHASE3":3799,"PHASE4":3801,"NA":3803},{"trials":3790,"activeCount":117},[],{"trials":3792,"activeCount":117},[3793],{"nctId":1893,"briefTitle":1894,"status":387,"phases":3794,"primaryCompletion":1896,"completion":487,"start":1897,"enrollment":164,"conditions":3795,"interventions":3796},[84],[1089],[1092,1900,629,1901],{"trials":3798,"activeCount":117},[],{"trials":3800,"activeCount":117},[],{"trials":3802,"activeCount":117},[],{"trials":3804,"activeCount":117},[],{"intervention":1901,"totalTrials":134,"cells":3806},{"EARLY_PHASE1":3807,"PHASE1":3809,"PHASE2":3815,"PHASE3":3817,"PHASE4":3819,"NA":3821},{"trials":3808,"activeCount":117},[],{"trials":3810,"activeCount":117},[3811],{"nctId":1893,"briefTitle":1894,"status":387,"phases":3812,"primaryCompletion":1896,"completion":487,"start":1897,"enrollment":164,"conditions":3813,"interventions":3814},[84],[1089],[1092,1900,629,1901],{"trials":3816,"activeCount":117},[],{"trials":3818,"activeCount":117},[],{"trials":3820,"activeCount":117},[],{"trials":3822,"activeCount":117},[],{"intervention":3824,"totalTrials":134,"cells":3825},"lyophilized black raspberry confection",{"EARLY_PHASE1":3826,"PHASE1":3828,"PHASE2":3844,"PHASE3":3846,"PHASE4":3848,"NA":3850},{"trials":3827,"activeCount":117},[],{"trials":3829,"activeCount":117},[3830],{"nctId":3831,"briefTitle":3832,"status":99,"phases":3833,"primaryCompletion":3834,"completion":3835,"start":3836,"enrollment":3837,"conditions":3838,"interventions":3843},"NCT01823562","Aborption and Metabolism of Lyophilized Black Raspberry Food Products in Men With Prostate Cancer Undergoing Surgery",[84],"2013-08-01","2025-11-12","2012-10-17",60,[3839,3840,3841,3842],"Stage I Prostate Cancer","Stage IIA Prostate Cancer","Stage IIB Prostate Cancer","Stage III Prostate Cancer",[3824],{"trials":3845,"activeCount":117},[],{"trials":3847,"activeCount":117},[],{"trials":3849,"activeCount":117},[],{"trials":3851,"activeCount":117},[],{"intervention":3853,"totalTrials":134,"cells":3854},"HDAC Inhibitor AR-42",{"EARLY_PHASE1":3855,"PHASE1":3857,"PHASE2":3869,"PHASE3":3871,"PHASE4":3873,"NA":3875},{"trials":3856,"activeCount":117},[],{"trials":3858,"activeCount":117},[3859],{"nctId":3860,"briefTitle":3861,"status":99,"phases":3862,"primaryCompletion":3863,"completion":3864,"start":3865,"enrollment":1990,"conditions":3866,"interventions":3867},"NCT02569320","HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma",[84],"2020-11-14","2021-03-10","2016-05-20",[2980],[444,3853,3868],"Pomalidomide",{"trials":3870,"activeCount":117},[],{"trials":3872,"activeCount":117},[],{"trials":3874,"activeCount":117},[],{"trials":3876,"activeCount":117},[],{"intervention":3868,"totalTrials":134,"cells":3878},{"EARLY_PHASE1":3879,"PHASE1":3881,"PHASE2":3887,"PHASE3":3889,"PHASE4":3891,"NA":3893},{"trials":3880,"activeCount":117},[],{"trials":3882,"activeCount":117},[3883],{"nctId":3860,"briefTitle":3861,"status":99,"phases":3884,"primaryCompletion":3863,"completion":3864,"start":3865,"enrollment":1990,"conditions":3885,"interventions":3886},[84],[2980],[444,3853,3868],{"trials":3888,"activeCount":117},[],{"trials":3890,"activeCount":117},[],{"trials":3892,"activeCount":117},[],{"trials":3894,"activeCount":117},[],{"intervention":3896,"totalTrials":134,"cells":3897},"Lorcaserin",{"EARLY_PHASE1":3898,"PHASE1":3900,"PHASE2":3913,"PHASE3":3915,"PHASE4":3917,"NA":3919},{"trials":3899,"activeCount":117},[],{"trials":3901,"activeCount":117},[3902],{"nctId":3903,"briefTitle":3904,"status":1108,"phases":3905,"primaryCompletion":3906,"completion":3906,"start":3907,"enrollment":117,"conditions":3908,"interventions":3911},"NCT04205071","Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal or Breast Cancer",[84],"2021-12-31","2020-11-01",[29,353,354,18,355,356,21,357,358,359,439,3909,3910,360,361,362,363,364,365,366,367,368,369,441],"Chemotherapy-Induced Peripheral Neuropathy","Digestive System Carcinoma",[3896,3912],"Lorcaserin Hydrochloride",{"trials":3914,"activeCount":117},[],{"trials":3916,"activeCount":117},[],{"trials":3918,"activeCount":117},[],{"trials":3920,"activeCount":117},[],{"intervention":3912,"totalTrials":134,"cells":3922},{"EARLY_PHASE1":3923,"PHASE1":3925,"PHASE2":3931,"PHASE3":3933,"PHASE4":3935,"NA":3937},{"trials":3924,"activeCount":117},[],{"trials":3926,"activeCount":117},[3927],{"nctId":3903,"briefTitle":3904,"status":1108,"phases":3928,"primaryCompletion":3906,"completion":3906,"start":3907,"enrollment":117,"conditions":3929,"interventions":3930},[84],[29,353,354,18,355,356,21,357,358,359,439,3909,3910,360,361,362,363,364,365,366,367,368,369,441],[3896,3912],{"trials":3932,"activeCount":117},[],{"trials":3934,"activeCount":117},[],{"trials":3936,"activeCount":117},[],{"trials":3938,"activeCount":117},[],{"intervention":603,"totalTrials":134,"cells":3940},{"EARLY_PHASE1":3941,"PHASE1":3943,"PHASE2":3949,"PHASE3":3951,"PHASE4":3953,"NA":3955},{"trials":3942,"activeCount":117},[],{"trials":3944,"activeCount":117},[3945],{"nctId":596,"briefTitle":597,"status":99,"phases":3946,"completion":599,"start":600,"conditions":3947,"interventions":3948},[84],[313],[380,603,604],{"trials":3950,"activeCount":117},[],{"trials":3952,"activeCount":117},[],{"trials":3954,"activeCount":117},[],{"trials":3956,"activeCount":117},[],{"intervention":604,"totalTrials":134,"cells":3958},{"EARLY_PHASE1":3959,"PHASE1":3961,"PHASE2":3967,"PHASE3":3969,"PHASE4":3971,"NA":3973},{"trials":3960,"activeCount":117},[],{"trials":3962,"activeCount":117},[3963],{"nctId":596,"briefTitle":597,"status":99,"phases":3964,"completion":599,"start":600,"conditions":3965,"interventions":3966},[84],[313],[380,603,604],{"trials":3968,"activeCount":117},[],{"trials":3970,"activeCount":117},[],{"trials":3972,"activeCount":117},[],{"trials":3974,"activeCount":117},[],{"intervention":3976,"totalTrials":134,"cells":3977},"carfilzomib",{"EARLY_PHASE1":3978,"PHASE1":3980,"PHASE2":3992,"PHASE3":3994,"PHASE4":3996,"NA":3998},{"trials":3979,"activeCount":117},[],{"trials":3981,"activeCount":117},[3982],{"nctId":3983,"briefTitle":3984,"status":99,"phases":3985,"primaryCompletion":3986,"completion":3987,"start":1724,"enrollment":621,"conditions":3988,"interventions":3991},"NCT01212380","Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)",[84],"2014-07","2015-09",[3989,3990,1854,1855,1072],"B-cell Chronic Lymphocytic Leukemia","Hematopoietic\u002FLymphoid Cancer",[3976],{"trials":3993,"activeCount":117},[],{"trials":3995,"activeCount":117},[],{"trials":3997,"activeCount":117},[],{"trials":3999,"activeCount":117},[],{"intervention":2315,"totalTrials":134,"cells":4001},{"EARLY_PHASE1":4002,"PHASE1":4004,"PHASE2":4010,"PHASE3":4012,"PHASE4":4014,"NA":4016},{"trials":4003,"activeCount":117},[],{"trials":4005,"activeCount":117},[4006],{"nctId":2305,"briefTitle":2306,"status":99,"phases":4007,"primaryCompletion":2308,"completion":2309,"start":2310,"enrollment":490,"conditions":4008,"interventions":4009},[84],[2312,2313],[2315,2316],{"trials":4011,"activeCount":117},[],{"trials":4013,"activeCount":117},[],{"trials":4015,"activeCount":117},[],{"trials":4017,"activeCount":117},[],{"intervention":381,"totalTrials":134,"cells":4019},{"EARLY_PHASE1":4020,"PHASE1":4022,"PHASE2":4028,"PHASE3":4030,"PHASE4":4032,"NA":4034},{"trials":4021,"activeCount":117},[],{"trials":4023,"activeCount":117},[4024],{"nctId":374,"briefTitle":375,"status":309,"phases":4025,"start":377,"conditions":4026,"interventions":4027},[84],[313],[380,381,316],{"trials":4029,"activeCount":117},[],{"trials":4031,"activeCount":117},[],{"trials":4033,"activeCount":117},[],{"trials":4035,"activeCount":117},[],{"intervention":2061,"totalTrials":134,"cells":4037},{"EARLY_PHASE1":4038,"PHASE1":4040,"PHASE2":4046,"PHASE3":4048,"PHASE4":4050,"NA":4052},{"trials":4039,"activeCount":117},[],{"trials":4041,"activeCount":117},[4042],{"nctId":2051,"briefTitle":2052,"status":99,"phases":4043,"primaryCompletion":2054,"completion":2055,"start":2056,"enrollment":16,"conditions":4044,"interventions":4045},[84],[1089,2058,2059],[2061,1694],{"trials":4047,"activeCount":117},[],{"trials":4049,"activeCount":117},[],{"trials":4051,"activeCount":117},[],{"trials":4053,"activeCount":117},[],{"intervention":1787,"totalTrials":134,"cells":4055},{"EARLY_PHASE1":4056,"PHASE1":4058,"PHASE2":4064,"PHASE3":4066,"PHASE4":4068,"NA":4070},{"trials":4057,"activeCount":117},[],{"trials":4059,"activeCount":117},[4060],{"nctId":1755,"briefTitle":1756,"status":1108,"phases":4061,"primaryCompletion":1758,"completion":1758,"start":1758,"enrollment":117,"conditions":4062,"interventions":4063},[84],[1760,1761,1762,1763,1764,1765,1766,1767,1768,1769,1770,1771,1772,1773,1774,1775,1776,1777,1778,1779,1780,1781,1782,1783,1784],[417,1139,1786,1787,1788],{"trials":4065,"activeCount":117},[],{"trials":4067,"activeCount":117},[],{"trials":4069,"activeCount":117},[],{"trials":4071,"activeCount":117},[],{"intervention":4073,"totalTrials":134,"cells":4074},"TheraSphere",{"EARLY_PHASE1":4075,"PHASE1":4090,"PHASE2":4092,"PHASE3":4094,"PHASE4":4096,"NA":4098},{"trials":4076,"activeCount":117},[4077],{"nctId":4078,"briefTitle":4079,"status":99,"phases":4080,"primaryCompletion":4081,"completion":4081,"start":4082,"enrollment":4083,"conditions":4084,"interventions":4089},"NCT02072356","Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery",[83],"2021-06-15","2010-10-11",290,[4085,4086,4087,4088],"Adult Primary Hepatocellular Carcinoma","Advanced Adult Primary Liver Cancer","Localized Unresectable Adult Primary Liver Cancer","Recurrent Adult Primary Liver Cancer",[4073],{"trials":4091,"activeCount":117},[],{"trials":4093,"activeCount":117},[],{"trials":4095,"activeCount":117},[],{"trials":4097,"activeCount":117},[],{"trials":4099,"activeCount":117},[],{"intervention":4101,"totalTrials":134,"cells":4102},"18F-FDG",{"EARLY_PHASE1":4103,"PHASE1":4114,"PHASE2":4116,"PHASE3":4118,"PHASE4":4120,"NA":4122},{"trials":4104,"activeCount":117},[4105],{"nctId":4106,"briefTitle":4107,"status":99,"phases":4108,"primaryCompletion":4109,"completion":4109,"start":2324,"enrollment":4110,"conditions":4111,"interventions":4112},"NCT00816335","Fludeoxyglucose F 18 PET\u002FCT Imaging in Finding Cancer in Patients Undergoing Surgery for Solid Tumors",[83],"2011-08",65,[313],[4101,4113],"18F-FDG for patients with Bladder Cancer",{"trials":4115,"activeCount":117},[],{"trials":4117,"activeCount":117},[],{"trials":4119,"activeCount":117},[],{"trials":4121,"activeCount":117},[],{"trials":4123,"activeCount":117},[],{"intervention":4113,"totalTrials":134,"cells":4125},{"EARLY_PHASE1":4126,"PHASE1":4132,"PHASE2":4134,"PHASE3":4136,"PHASE4":4138,"NA":4140},{"trials":4127,"activeCount":117},[4128],{"nctId":4106,"briefTitle":4107,"status":99,"phases":4129,"primaryCompletion":4109,"completion":4109,"start":2324,"enrollment":4110,"conditions":4130,"interventions":4131},[83],[313],[4101,4113],{"trials":4133,"activeCount":117},[],{"trials":4135,"activeCount":117},[],{"trials":4137,"activeCount":117},[],{"trials":4139,"activeCount":117},[],{"trials":4141,"activeCount":117},[],{"intervention":4143,"totalTrials":134,"cells":4144},"typhoid vaccine",{"EARLY_PHASE1":4145,"PHASE1":4157,"PHASE2":4159,"PHASE3":4161,"PHASE4":4163,"NA":4165},{"trials":4146,"activeCount":117},[4147],{"nctId":4148,"briefTitle":4149,"status":99,"phases":4150,"primaryCompletion":4151,"completion":4151,"start":2372,"enrollment":4152,"conditions":4153,"interventions":4156},"NCT02415387","Typhoid Vaccine in Testing Response to Immune Stress in Patients With Stage I-IIIA Breast Cancer",[83],"2021-04-27",172,[4154,3053,4155,2449,2450,2451,2452,2453],"Cognitive Side Effects of Cancer Therapy","Recurrent Breast Carcinoma",[4143],{"trials":4158,"activeCount":117},[],{"trials":4160,"activeCount":117},[],{"trials":4162,"activeCount":117},[],{"trials":4164,"activeCount":117},[],{"trials":4166,"activeCount":117},[],{"intervention":444,"totalTrials":92,"cells":4168},{"EARLY_PHASE1":4169,"PHASE1":4171,"PHASE2":4181,"PHASE3":4191,"PHASE4":4197,"NA":4199},{"trials":4170,"activeCount":117},[],{"trials":4172,"activeCount":117},[4173,4177],{"nctId":1741,"briefTitle":1742,"status":99,"phases":4174,"primaryCompletion":1744,"completion":1745,"start":1746,"enrollment":589,"conditions":4175,"interventions":4176},[84],[413],[1749,1139,444],{"nctId":3860,"briefTitle":3861,"status":99,"phases":4178,"primaryCompletion":3863,"completion":3864,"start":3865,"enrollment":1990,"conditions":4179,"interventions":4180},[84],[2980],[444,3853,3868],{"trials":4182,"activeCount":117},[4183,4187],{"nctId":2633,"briefTitle":2634,"status":99,"phases":4184,"primaryCompletion":1123,"completion":2141,"start":2636,"enrollment":33,"conditions":4185,"interventions":4186},[85],[1829],[2624,2639,444,2640],{"nctId":1082,"briefTitle":1083,"status":309,"phases":4188,"primaryCompletion":1085,"start":1086,"enrollment":1087,"conditions":4189,"interventions":4190},[85],[1089],[1091,1092,1093,1094,1095,1096,1097,1098,1099,1100,1101,1102,1103,1104],{"trials":4192,"activeCount":117},[4193],{"nctId":431,"briefTitle":432,"status":99,"phases":4194,"primaryCompletion":434,"completion":434,"start":435,"enrollment":436,"conditions":4195,"interventions":4196},[85,86],[438,29,353,354,18,355,356,21,357,358,359,439,32,440,360,361,362,363,364,365,366,367,368,369,441],[443,444,445,446,257,447],{"trials":4198,"activeCount":117},[],{"trials":4200,"activeCount":117},[4201],{"nctId":4202,"briefTitle":4203,"status":99,"phases":4204,"primaryCompletion":4109,"completion":4109,"start":4205,"enrollment":250,"conditions":4206,"interventions":4208},"NCT01640340","Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)",[88],"2011-01",[4207],"Malignant Neoplasm",[4209,4210,4211,1093],"aprepitant","palonosetron hydrochloride","ondansetron",{"intervention":4213,"totalTrials":9,"cells":4214},"porfimer sodium",{"EARLY_PHASE1":4215,"PHASE1":4217,"PHASE2":4219,"PHASE3":4221,"PHASE4":4223,"NA":4225},{"trials":4216,"activeCount":117},[],{"trials":4218,"activeCount":117},[],{"trials":4220,"activeCount":117},[],{"trials":4222,"activeCount":117},[],{"trials":4224,"activeCount":117},[],{"trials":4226,"activeCount":117},[4227,4235],{"nctId":4228,"briefTitle":4229,"status":99,"phases":4230,"primaryCompletion":4231,"completion":4231,"start":4232,"enrollment":399,"conditions":4233,"interventions":4234},"NCT00754910","Photodynamic Therapy Using Porfimer Sodium in Treating Patients With Non-Small Cell Lung Cancer And Bronchial Disease",[],"2016-03","2008-12",[2326],[4213],{"nctId":4236,"briefTitle":4237,"status":1108,"phases":4238,"primaryCompletion":4239,"completion":4239,"start":4240,"enrollment":117,"conditions":4241,"interventions":4245},"NCT02106559","Photodynamic Therapy During Surgery in Treating Patients With Pleural Malignancy",[88],"2016-01-29","2014-09-04",[4242,627,4243,4244],"Stage III Malignant Mesothelioma","Stage IV Malignant Mesothelioma","Stage IV Non-small Cell Lung Cancer",[4213,4246],"photodynamic therapy",{"intervention":1100,"totalTrials":9,"cells":4248},{"EARLY_PHASE1":4249,"PHASE1":4251,"PHASE2":4253,"PHASE3":4259,"PHASE4":4261,"NA":4263},{"trials":4250,"activeCount":117},[],{"trials":4252,"activeCount":117},[],{"trials":4254,"activeCount":117},[4255],{"nctId":1082,"briefTitle":1083,"status":309,"phases":4256,"primaryCompletion":1085,"start":1086,"enrollment":1087,"conditions":4257,"interventions":4258},[85],[1089],[1091,1092,1093,1094,1095,1096,1097,1098,1099,1100,1101,1102,1103,1104],{"trials":4260,"activeCount":117},[],{"trials":4262,"activeCount":117},[],{"trials":4264,"activeCount":117},[4265],{"nctId":4266,"briefTitle":4267,"status":1108,"phases":4268,"primaryCompletion":1085,"completion":1085,"start":2164,"enrollment":117,"conditions":4269,"interventions":4270},"NCT01789892","Methylprednisolone Before Fludeoxyglucose-Labeled Positron Emission Tomography in Patients With Lung Cancer",[88],[2326],[1100],{"intervention":4246,"totalTrials":134,"cells":4272},{"EARLY_PHASE1":4273,"PHASE1":4275,"PHASE2":4277,"PHASE3":4279,"PHASE4":4281,"NA":4283},{"trials":4274,"activeCount":117},[],{"trials":4276,"activeCount":117},[],{"trials":4278,"activeCount":117},[],{"trials":4280,"activeCount":117},[],{"trials":4282,"activeCount":117},[],{"trials":4284,"activeCount":117},[4285],{"nctId":4236,"briefTitle":4237,"status":1108,"phases":4286,"primaryCompletion":4239,"completion":4239,"start":4240,"enrollment":117,"conditions":4287,"interventions":4288},[88],[4242,627,4243,4244],[4213,4246],{"intervention":4290,"totalTrials":134,"cells":4291},"indocyanine green solution",{"EARLY_PHASE1":4292,"PHASE1":4294,"PHASE2":4296,"PHASE3":4298,"PHASE4":4300,"NA":4302},{"trials":4293,"activeCount":117},[],{"trials":4295,"activeCount":117},[],{"trials":4297,"activeCount":117},[],{"trials":4299,"activeCount":117},[],{"trials":4301,"activeCount":117},[],{"trials":4303,"activeCount":117},[4304],{"nctId":4305,"briefTitle":4306,"status":99,"phases":4307,"primaryCompletion":1869,"completion":4308,"start":4309,"enrollment":4310,"conditions":4311,"interventions":4313},"NCT01818739","Lymph Node Mapping in Patients With Endometrial Cancer",[88],"2017-03-31","2013-03",204,[4312],"Endometrial Cancer",[4290,4314],"isosulfan blue",{"intervention":4314,"totalTrials":134,"cells":4316},{"EARLY_PHASE1":4317,"PHASE1":4319,"PHASE2":4321,"PHASE3":4323,"PHASE4":4325,"NA":4327},{"trials":4318,"activeCount":117},[],{"trials":4320,"activeCount":117},[],{"trials":4322,"activeCount":117},[],{"trials":4324,"activeCount":117},[],{"trials":4326,"activeCount":117},[],{"trials":4328,"activeCount":117},[4329],{"nctId":4305,"briefTitle":4306,"status":99,"phases":4330,"primaryCompletion":1869,"completion":4308,"start":4309,"enrollment":4310,"conditions":4331,"interventions":4332},[88],[4312],[4290,4314],{"intervention":4334,"totalTrials":134,"cells":4335},"Gadolinium",{"EARLY_PHASE1":4336,"PHASE1":4338,"PHASE2":4340,"PHASE3":4342,"PHASE4":4344,"NA":4346},{"trials":4337,"activeCount":117},[],{"trials":4339,"activeCount":117},[],{"trials":4341,"activeCount":117},[],{"trials":4343,"activeCount":117},[],{"trials":4345,"activeCount":117},[],{"trials":4347,"activeCount":117},[4348],{"nctId":4349,"briefTitle":4350,"status":1108,"phases":4351,"primaryCompletion":4352,"completion":4352,"start":4353,"enrollment":117,"conditions":4354,"interventions":4356},"NCT02590497","Correlation Between the Genetic and Neuroimaging Signatures in Newly Diagnosed Glioblastoma Patients Before Surgery",[88],"2017-10-26","2016-03-20",[4355],"Glioblastoma",[4334],{"intervention":4358,"totalTrials":134,"cells":4359},"acetylsalicylic acid",{"EARLY_PHASE1":4360,"PHASE1":4362,"PHASE2":4364,"PHASE3":4366,"PHASE4":4368,"NA":4370},{"trials":4361,"activeCount":117},[],{"trials":4363,"activeCount":117},[],{"trials":4365,"activeCount":117},[],{"trials":4367,"activeCount":117},[],{"trials":4369,"activeCount":117},[],{"trials":4371,"activeCount":117},[4372],{"nctId":4373,"briefTitle":4374,"status":99,"phases":4375,"primaryCompletion":4376,"completion":4376,"start":1724,"enrollment":33,"conditions":4377,"interventions":4382},"NCT01696760","Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology",[88],"2012-12",[4378,4379,4380,4381],"Bone Metastases","Musculoskeletal Cancer","Soft Tissue Sarcoma","Thromboembolism",[4358,4383],"enoxaparin",{"intervention":4383,"totalTrials":134,"cells":4385},{"EARLY_PHASE1":4386,"PHASE1":4388,"PHASE2":4390,"PHASE3":4392,"PHASE4":4394,"NA":4396},{"trials":4387,"activeCount":117},[],{"trials":4389,"activeCount":117},[],{"trials":4391,"activeCount":117},[],{"trials":4393,"activeCount":117},[],{"trials":4395,"activeCount":117},[],{"trials":4397,"activeCount":117},[4398],{"nctId":4373,"briefTitle":4374,"status":99,"phases":4399,"primaryCompletion":4376,"completion":4376,"start":1724,"enrollment":33,"conditions":4400,"interventions":4401},[88],[4378,4379,4380,4381],[4358,4383],{"intervention":4403,"totalTrials":134,"cells":4404},"Streptococcus pneumoniae",{"EARLY_PHASE1":4405,"PHASE1":4407,"PHASE2":4409,"PHASE3":4411,"PHASE4":4413,"NA":4415},{"trials":4406,"activeCount":117},[],{"trials":4408,"activeCount":117},[],{"trials":4410,"activeCount":117},[],{"trials":4412,"activeCount":117},[],{"trials":4414,"activeCount":117},[],{"trials":4416,"activeCount":117},[4417],{"nctId":4418,"briefTitle":4419,"status":99,"phases":4420,"primaryCompletion":4421,"completion":4421,"start":4422,"enrollment":164,"conditions":4423,"interventions":4425},"NCT00569309","Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma",[88],"2011-07-29","2007-12-12",[1113,4424,3427],"Multiple Myeloma and Plasma Cell Neoplasm",[4403],{"intervention":4427,"totalTrials":134,"cells":4428},"LS tumor screening",{"EARLY_PHASE1":4429,"PHASE1":4431,"PHASE2":4433,"PHASE3":4435,"PHASE4":4437,"NA":4439},{"trials":4430,"activeCount":117},[],{"trials":4432,"activeCount":117},[],{"trials":4434,"activeCount":117},[],{"trials":4436,"activeCount":117},[],{"trials":4438,"activeCount":117},[],{"trials":4440,"activeCount":117},[4441],{"nctId":4442,"briefTitle":4443,"status":99,"phases":4444,"primaryCompletion":4445,"completion":4445,"start":4446,"enrollment":4447,"conditions":4448,"interventions":4450},"NCT01850654","Ohio Colorectal Cancer Prevention Initiative",[88],"2018-01-02","2012-12-26",3470,[4449,3370],"Lynch Syndrome",[4427,4451],"Genetic testing",{"intervention":4451,"totalTrials":134,"cells":4453},{"EARLY_PHASE1":4454,"PHASE1":4456,"PHASE2":4458,"PHASE3":4460,"PHASE4":4462,"NA":4464},{"trials":4455,"activeCount":117},[],{"trials":4457,"activeCount":117},[],{"trials":4459,"activeCount":117},[],{"trials":4461,"activeCount":117},[],{"trials":4463,"activeCount":117},[],{"trials":4465,"activeCount":117},[4466],{"nctId":4442,"briefTitle":4443,"status":99,"phases":4467,"primaryCompletion":4445,"completion":4445,"start":4446,"enrollment":4447,"conditions":4468,"interventions":4469},[88],[4449,3370],[4427,4451],{"intervention":4209,"totalTrials":134,"cells":4471},{"EARLY_PHASE1":4472,"PHASE1":4474,"PHASE2":4476,"PHASE3":4478,"PHASE4":4480,"NA":4482},{"trials":4473,"activeCount":117},[],{"trials":4475,"activeCount":117},[],{"trials":4477,"activeCount":117},[],{"trials":4479,"activeCount":117},[],{"trials":4481,"activeCount":117},[],{"trials":4483,"activeCount":117},[4484],{"nctId":4202,"briefTitle":4203,"status":99,"phases":4485,"primaryCompletion":4109,"completion":4109,"start":4205,"enrollment":250,"conditions":4486,"interventions":4487},[88],[4207],[4209,4210,4211,1093],{"intervention":4210,"totalTrials":134,"cells":4489},{"EARLY_PHASE1":4490,"PHASE1":4492,"PHASE2":4494,"PHASE3":4496,"PHASE4":4498,"NA":4500},{"trials":4491,"activeCount":117},[],{"trials":4493,"activeCount":117},[],{"trials":4495,"activeCount":117},[],{"trials":4497,"activeCount":117},[],{"trials":4499,"activeCount":117},[],{"trials":4501,"activeCount":117},[4502],{"nctId":4202,"briefTitle":4203,"status":99,"phases":4503,"primaryCompletion":4109,"completion":4109,"start":4205,"enrollment":250,"conditions":4504,"interventions":4505},[88],[4207],[4209,4210,4211,1093],{"intervention":4211,"totalTrials":134,"cells":4507},{"EARLY_PHASE1":4508,"PHASE1":4510,"PHASE2":4512,"PHASE3":4514,"PHASE4":4516,"NA":4518},{"trials":4509,"activeCount":117},[],{"trials":4511,"activeCount":117},[],{"trials":4513,"activeCount":117},[],{"trials":4515,"activeCount":117},[],{"trials":4517,"activeCount":117},[],{"trials":4519,"activeCount":117},[4520],{"nctId":4202,"briefTitle":4203,"status":99,"phases":4521,"primaryCompletion":4109,"completion":4109,"start":4205,"enrollment":250,"conditions":4522,"interventions":4523},[88],[4207],[4209,4210,4211,1093],{"intervention":4525,"totalTrials":134,"cells":4526},"lidocaine",{"EARLY_PHASE1":4527,"PHASE1":4529,"PHASE2":4531,"PHASE3":4533,"PHASE4":4535,"NA":4537},{"trials":4528,"activeCount":117},[],{"trials":4530,"activeCount":117},[],{"trials":4532,"activeCount":117},[],{"trials":4534,"activeCount":117},[],{"trials":4536,"activeCount":117},[],{"trials":4538,"activeCount":117},[4539],{"nctId":4540,"briefTitle":4541,"status":99,"phases":4542,"primaryCompletion":3298,"completion":4543,"start":1689,"enrollment":4544,"conditions":4545,"interventions":4547},"NCT00456872","Contrast of Buffered Vs. Unbuffered Lidocaine in Bone Marrow Biopsies",[88],"2007-09",49,[4546],"Pain",[4525]]